[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1799
1. Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO: Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park); 2005 Feb;19(2):213-28; discussion 228, 233-6, 239
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma: expanding therapeutic options.
  • The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide.
  • Long-term disease-free survival is possible in select patient subgroups after treatment, but very late relapses suggest that quiescent lymphoma cells might be harbored for long periods of time.
  • Radiation therapy is the mainstay of treatment for limited-stage follicular lymphoma, but there is some experience with chemotherapy and combined chemoradiation.
  • Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, and proteasome inhibitors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770890.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines; 0 / Oligonucleotides, Antisense; 0 / Proteasome Inhibitors
  • [Number-of-references] 148
  •  go-up   go-down


2. Abid MB, Nasim F, Anwar K, Pervez S: Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev; 2005 Oct-Dec;6(4):531-4
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic?
  • There has been a recent concern among oncological clinicians and pathologists of our region regarding the disproportionate increase in the number of patients presenting with diffuse large B cell lymphoma (DLBCL).
  • A total of 780 specimens were collected over last half decade from cases classified as adult Non Hodgkin's lymphoma (NHL).
  • Nodal-NHLs constituted 42.2 % of all adult NHLs, with the cervical lymph nodes as the most frequent nodal site of presentation.
  • [MeSH-major] Disease Outbreaks. Lymphoma, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436006.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


3. Smith SK, Zimmerman S, Williams CS, Preisser JS, Clipp EC: Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors. J Clin Oncol; 2008 Feb 20;26(6):934-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors.
  • Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable.
  • PATIENTS AND METHODS: A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis.

  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Fam Psychol. 2004 Sep;18(3):493-504 [15382974.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2214-24 [1394054.001]
  • [Cites] J Consult Clin Psychol. 1995 Dec;63(6):981-6 [8543720.001]
  • [Cites] Psychosomatics. 1996 May-Jun;37(3):254-61 [8849502.001]
  • [Cites] Behav Res Ther. 1996 Aug;34(8):669-73 [8870294.001]
  • [Cites] Annu Rev Psychol. 1997;48:449-80 [9046566.001]
  • [Cites] J Trauma Stress. 1998 Apr;11(2):189-203 [9565911.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):177-82 [16862538.001]
  • [Cites] Psychooncology. 2007 Oct;16(10):895-903 [17245695.001]
  • [Cites] Psychosomatics. 2001 Mar-Apr;42(2):133-40 [11239126.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • [Cites] Psychooncology. 2002 Nov-Dec;11(6):479-94 [12476430.001]
  • [Cites] Arthritis Rheum. 2003 Apr 15;49(2):156-63 [12687505.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • (PMID = 18281667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101492-01A2; United States / NCI NIH HHS / CA / R03 CA101492; United States / NCI NIH HHS / CA / R03 CA101492-01A2; United States / NCI NIH HHS / CA / R03-CA-101492
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS261515; NLM/ PMC3025533
  •  go-up   go-down


Advertisement
4. Gemmati D, Ongaro A, Tognazzo S, Catozzi L, Federici F, Mauro E, Della Porta M, Campioni D, Bardi A, Gilli G, Pellati A, Caruso A, Scapoli GL, De Mattei M: Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica; 2007 Apr;92(4):478-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
  • We analyzed 110 patients with high-grade non-Hodgkin's lymphoma (NHL), 68 of whom were eligible for a chemotherapy combination containing methotrexate (MACOP-B) and 42 for chemotherapy without methotrexate (CHOP).
  • INTERPRETATION AND CONCLUSIONS: Our data suggest that MTHFR gene variants play a critical role in NHL outcome, possibly by interfering with the action of methotrexate with significant effects on toxicity and survival.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Lymphoma, Large B-Cell, Diffuse / genetics. Methotrexate / pharmacokinetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Substitution. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug-Induced Liver Injury / epidemiology. Drug-Induced Liver Injury / etiology. Female. Genotype. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Mucositis / chemically induced. Mucositis / epidemiology. Prednisone / administration & dosage. Prednisone / adverse effects. Risk. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859137 for PMID:17488658 [PharmGKB] .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488658.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol
  •  go-up   go-down


5. Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV: Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients. Am J Hematol; 2008 Apr;83(4):279-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients.
  • Using allele-specific hybridization on the biochip 76 T-cell non-Hodgkin's lymphoma (NHL) patients, 83 B-cell chronic lymphocytic leukemia (B-CLL) patients, and 177 healthy donors were tested.
  • The GSTM1 null genotype was more frequent in NHL patients relative to controls (OR = 1.82, 95% CI = 1.1-3.1).
  • Thus, our findings show the association between polymorphic alleles of CYP1A1, GSTM1, and CYP2C9 genes and the risk to develop NHL or B-CLL.
  • [MeSH-major] Biotransformation / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Xenobiotics / pharmacokinetics
  • [MeSH-minor] Adult. Alleles. Arylamine N-Acetyltransferase / genetics. Carcinogens, Environmental / pharmacokinetics. Cytochrome P-450 Enzyme System / genetics. Female. Ferredoxin-NADP Reductase / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Humans. Male. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Nucleic Acid Hybridization. Risk Factors. Russia / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18061941.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 0 / Xenobiotics; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


6. Asfour IA, Fayek M, Raouf S, Soliman M, Hegab HM, El-Desoky H, Saleh R, Moussa MA: The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival. Biol Trace Elem Res; 2007;120(1-3):1-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival.
  • The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the expression of Bcl-2 in patients with non-Hodgkin's lymphoma (NHL).
  • Fifty patients with newly diagnosed NHL were randomly divided into two groups.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Sodium Selenite / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Down-Regulation. Doxorubicin / therapeutic use. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. SODIUM SELENITE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916949.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; HIW548RQ3W / Sodium Selenite; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Kuittinen T, Husso-Saastamoinen M, Sipola P, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, Jantunen E, Hartikainen J: Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant; 2005 Dec;36(12):1077-82
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
  • We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adult non-Hodgkin's lymphoma (NHL) patients receiving CY 1500 mg/m2/day as a part of BEAC high-dose therapy (HDT).
  • To conclude, high-dose CY results in very acute cardiac toxicity characterised by enlargement of the heart chambers in NHL patients previously treated with anthracyclines.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart / drug effects. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cardiovascular System / pathology. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Natriuretic Peptides / blood. Peptides / chemistry. Prospective Studies. Time Factors. Transplantation, Autologous. Ventricular Dysfunction, Left / diagnosis. Ventricular Function, Left

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247436.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Natriuretic Peptides; 0 / Peptides; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine; BAEC protocol
  •  go-up   go-down


8. Kollár B, Rajnics P, Hunyady B, Zeleznik E, Jakucs J, Egyed M: [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions]. Orv Hetil; 2009 Aug 30;150(35):1649-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].
  • [Transliterated title] Pimer gastrointestinalis non-Hodgkin-lymphoma két magyarországi régió beteganyaga alapján.
  • Over the past few decades, the occurrence of adult onset non-Hodgkin's lymphoma has significantly increased.
  • The treatment strategy for non-Hodgkin's lymphoma has changed over the past decade: chemo-immunotherapy has largely taken over surgical intervention, the dominant treatment option of the past.
  • METHODS: The authors present their experience with 48 patients with non-Hodgkin's lymphoma, affecting the gastrointestinal tract, treated in Kaposvár, in the Kaposi Mór Teaching Hospital and in Gyula, in the Pándy Kálmán County Hospital.
  • RESULTS: The most frequently involved GI organ was the stomach ( n = 26), with the dominant histological type of diffuse large B-cell lymphoma.
  • Patients with upper gastrointestinal tract involvement carried the best prognosis (IPI: 2.0); at the same time, patients with stomach lymphoma achieved the highest rate of remission (73%).
  • CONCLUSIONS: With chemo-immunotherapy the chances of a complete remission have significantly improved over the past decade, thus a significant portion of non-Hodgkin's lymphomas involving the gastrointestinal tract can be cured.
  • IPI index represents the most recognised indicator for assessing the prognosis of non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / therapy. Immunotherapy. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Hungary / epidemiology. Incidence. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Risk Assessment. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692309.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


9. Chaar BT, Salem P, Petruska PJ: Procarbazine for non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Apr;47(4):637-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Procarbazine for non-Hodgkin's lymphoma.
  • Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma.
  • It is most commonly used in the treatment of Hodgkin's disease.
  • The use of procarbazine-containing chemotherapeutic regimens in non-Hodgkin's lymphoma fell out of favor with the advent of CHOP.
  • We report two patients with relapsed and/or refractory follicular lymphoma that achieved a complete and durable remission with a prolonged course of daily procarbazine.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Procarbazine / therapeutic use
  • [MeSH-minor] Adult. Alkylating Agents / therapeutic use. Antineoplastic Agents / pharmacology. Enzyme Inhibitors / pharmacology. Female. Humans. Male. Middle Aged. Monoamine Oxidase Inhibitors / pharmacology. Remission Induction. Stem Cell Transplantation / methods

  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690522.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Monoamine Oxidase Inhibitors; 35S93Y190K / Procarbazine
  •  go-up   go-down


10. Gross TG, Termuhlen AM: Pediatric non-Hodgkin's lymphoma. Curr Oncol Rep; 2007 Nov;9(6):459-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually.
  • NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes.
  • Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy.
  • This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Curr Hematol Malig Rep. 2008 Jul;3(3):167-73 [20425462.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):186-93 [2915234.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):70-6 [15368550.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Feb;25(2):109-13 [12571460.001]
  • [Cites] Pediatr Dermatol. 2004 May-Jun;21(3):212-7 [15165197.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Neurosurg Focus. 2006 Nov 15;21(5):E8 [17134124.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2319-33 [11304786.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6481-8 [16170157.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1959-66 [11745271.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Leuk Lymphoma. 2001 Jul;42(3):399-405 [11699405.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):536-44 [10573576.001]
  • [Cites] Inflamm Bowel Dis. 2007 Aug;13(8):1024-30 [17480018.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):541-7 [15659500.001]
  • (PMID = 17991353.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


11. Townsend AR, Millward M, Price T, Mainwaring P, Spencer A, Longenecker A, Palladino MA, Lloyd GK, Spear MA, Padrik P: Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol; 2009 May 20;27(15_suppl):3582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm).
  • : 3582 Background: The novel structure (non-peptide based) of NPI-0052 (NPI) appears to lead to unique proteasome inhibition (PI), toxicology and signal transduction profiles.
  • METHODS: Patients with solid tumor, lymphoma or leukemia diagnoses without standard treatment options were treated with IV NPI on Days 1, 8 and 15 of 28-day cycles in a 3+3 design dose escalation to a Recommended Phase 2 Dose (RP2D).
  • Enrollment then began in 10 patient lymphoma and CLL RP2D cohorts.
  • Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Patte C, Ribrag V, Brugières L: [Non Hodgkin's lymphoma in adolescents]. Bull Cancer; 2007 Apr;94(4):339-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in adolescents].
  • [Transliterated title] Problématique de la prise en charge des adolescents atteints de lymphomes non hodgkiniens.
  • In France, adolescents (15-20 years) with non Hodgkin's lymphoma (NHL) are referred either to paediatric or to adult onco-haematological departments.
  • According to data obtained from regional tumour registries (covering about 10% of France), their 5 year survival rate was 59% whereas it was 87% for children (< or =14 years) treated for NHL during a similar period of time.
  • We reviewed the management of NHL either by the paediatricians or the onco-hematologists for adults.
  • The categories of NHL that are reviewed and whose clinical and biological characteristics are presented are: Burkitt, lymphoblastic and large cell, either B or anaplastic.
  • Further studies specific to the adolescents are needed to better know the biology of their lymphoma and to determine the best therapeutic approach.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Child. Clinical Protocols. France / epidemiology. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Medical Oncology / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449436.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 72
  •  go-up   go-down


13. Lazarus HM, Carreras J, Boudreau C, Loberiza FR Jr, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD, Center For International Blood & Marrow Transplant Research (CIBMTR): Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant; 2008 Dec;14(12):1323-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
  • To compare the clinical outcomes of older (age > or =55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL patients (<55 years) receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in 805 NHL patients aged > or =55 years to 1949 NHL patients <55 years during the years 1990-2000 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
  • Autologous HCT in older NHL patients is feasible, but most disease-related outcomes are statistically inferior to younger patients.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):840-6 [18541205.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(2A):204-10 [10816029.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(7):737-41 [11042654.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]
  • [Cites] Blood. 2002 May 1;99(9):3158-62 [11964278.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jun;9(6):383-8 [12813446.001]
  • [Cites] Blood. 2003 Jul 1;102(1):31-5 [12595317.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27 [14750077.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Vital Health Stat 13. 1991 Sep;(108):1-236 [1720910.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] N Engl J Med. 1994 Oct 20;331(16):1063-7 [8090167.001]
  • [Cites] Bone Marrow Transplant. 1994 Dec;14(6):981-7 [7711677.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1327-32 [8648391.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):18-25 [8996120.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(1):31-5 [9012928.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Clin Geriatr Med. 1997 May;13(2):251-63 [9115450.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):671-8 [9156243.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1193-6 [9674850.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1273-8 [10414915.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):1017-22 [16633361.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1166-71 [18272911.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1588-93 [10688812.001]
  • (PMID = 19041053.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-11; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83336; NLM/ PMC2638759
  •  go-up   go-down


14. Barthwal MS, Deoskar RB, Falleiro JJ, Singh P: Endobronchial non-Hodgkin's lymphoma. Indian J Chest Dis Allied Sci; 2005 Apr-Jun;47(2):117-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial non-Hodgkin's lymphoma.
  • Needle aspiration and endobronchial biopsy from the mass revealed it to be a case of anaplastic large cell lymphoma, a subtype of non-Hodgkin's lymphoma.
  • This report documents the rare presentation of non-Hodgkin's lymphoma as an endobronchial mass.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. India. Male. Risk Assessment. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832956.001).
  • [ISSN] 0377-9343
  • [Journal-full-title] The Indian journal of chest diseases & allied sciences
  • [ISO-abbreviation] Indian J Chest Dis Allied Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


15. Wang SS, Carreon JD, Hanchard B, Chanock S, Hisada M: Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica. Int J Cancer; 2009 Sep 15;125(6):1479-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica.
  • We evaluated whether risk of non-Hodgkin lymphoma (NHL), particularly adult T-cell leukemia/lymphoma (ATL) related to human T-lymphotropic virus (HTLV) infection was associated with 63 single nucleotide polymorphisms (SNPs) from 38 candidate genes.
  • The 395 NHL cases registered in Jamaica were matched by age, sex, calendar-year and HTLV serostatus to 309 controls from the same population.
  • Interleukin 13 (IL13) Ex4+98A>G SNP (rs20541) was associated with decreased NHL risk (OR(AG/AA) = 0.62,95% CI = 0.44-0.87, p = 0.006), as was vascular cell adhesion molecule-1, VCAM1 Ex9+149G>A SNP (rs1041163) (OR(CT) = 0.77, 95% CI = 0.54-1.10, OR(CC) = 0.35, 95% CI = 0.16-0.76, p-trend = 0.007).
  • [MeSH-major] HTLV-I Infections / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genetic Predisposition to Disease. Human T-lymphotropic virus 1 / immunology. Humans. Interleukin-13 / genetics. Interleukin-5 / genetics. Jamaica / epidemiology. Male. Middle Aged. Vascular Cell Adhesion Molecule-1 / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19533685.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL5 protein, human; 0 / Interleukin-13; 0 / Interleukin-5; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


16. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol; 2009 Aug;7(8):874-81
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
  • BACKGROUND & AIMS: Although anti-tumor necrosis factor (TNF) therapy can effectively treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's lymphoma (NHL).
  • A meta-analysis was performed to determine the rate of NHL in adult CD patients who have received anti-TNF therapy and to compare this rate with that of a population-based registry and a population of CD patients treated with immunomodulators.
  • Inclusion criteria included randomized controlled trials, cohort studies, or case series reporting on anti-TNF therapy in adult CD patients.
  • Standardized incidence ratios (SIR) were calculated by comparing the pooled rate of NHL with the expected rate of NHL derived from the Surveillance Epidemiology & End Results (SEER) database and a meta-analysis of CD patients treated with immunomodulators.
  • Among anti-TNF treated subjects, 13 cases of NHL were reported (6.1 per 10,000 patient-years).
  • Compared with the expected rate of NHL in the SEER database (1.9 per 10,000 patient-years), anti-TNF treated subjects had a significantly elevated risk (SIR, 3.23; 95% confidence interval, 1.5-6.9).
  • When compared with the NHL rate in CD patients treated with immunomodulators alone (4 per 10,000 patient-years), the SIR was 1.7 (95% confidence interval, 0.5-7.1).
  • CONCLUSIONS: The use of anti-TNF agents with immunomodulators is associated with an increased risk of NHL in adult CD patients, but the absolute rate of these events remains low and should be weighed against the substantial benefits associated with treatment.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):295-301 [14984376.001]
  • [Cites] Risk Anal. 2009 Jan;29(1):121-36 [18826414.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] Inflamm Bowel Dis. 2004 Mar;10(2):91-6 [15168807.001]
  • [Cites] Digestion. 2004;70(1):3-9 [15297773.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2308-12 [11007233.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Inflamm Bowel Dis. 2001 May;7 Suppl 1:S17-22 [11380038.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Am J Gastroenterol. 2003 Mar;98(3):608-12 [12650795.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):402-13 [14762776.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Aug;96(8):548-54; 554-8 [15449986.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):912-20 [15476155.001]
  • [Cites] Inflamm Bowel Dis. 1999 May;5(2):119-33 [10338381.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):164-8 [15720356.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):862-9 [15825070.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Korean J Gastroenterol. 2005 Jul;46(1):48-55 [16030404.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Jan;18(1):11-6 [16357613.001]
  • [Cites] Gut. 2006 Feb;55(2):228-33 [16120759.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1054-61 [16618399.001]
  • [Cites] Dis Colon Rectum. 2006 Dec;49(12):1837-41 [17041753.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80 [17311600.001]
  • [Cites] Gut. 2007 Sep;56(9):1232-9 [17299059.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1107:346-55 [17804562.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):769-79 [17628557.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9 [17904915.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):391-3 [18490372.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53 [18550004.001]
  • [Cites] Am J Gastroenterol. 2008 Aug;103(8):2015-22 [18564113.001]
  • [CommentIn] Clin Gastroenterol Hepatol. 2009 Oct;7(10):1139 [19465159.001]
  • (PMID = 19558997.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK078678-02; United States / NIDDK NIH HHS / DK / K23 DK078678; United States / NIDDK NIH HHS / DK / K23 DK078678-02; United States / NIDDK NIH HHS / DK / K23DK078678
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS184443; NLM/ PMC2846413
  •  go-up   go-down


17. Hayashi D, Lee JC, Devenney-Cakir B, Zaim S, Ounadjela S, Solal-Céligny P, Juweid M, Guermazi A: Follicular non-Hodgkin's lymphoma. Clin Radiol; 2010 May;65(5):408-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular non-Hodgkin's lymphoma.
  • Follicular non-Hodgkin's lymphoma (NHL) is a unique subtype of NHL, which is indolent, incurable with a high prevalence of residual mass after treatment, and may transform to more aggressive NHL.
  • The aim of this review is to (1) describe the histological and flow cytometry characteristics of follicular NHL;.
  • (2) introduce the Follicular Lymphoma International Prognostic Index 2 (FLIPI-2), which allows better treatment selection and patient stratification for clinical trials;.
  • (3) illustrate the classic and atypical ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET)/CT appearance of follicular NHL; and (4) characterize the appearance of nodal and extranodal follicular NHL with pathological correlation.
  • Imaging is essential in every step of the management of patients with follicular lymphoma.
  • Radiologists should be aware of possible active residual mass, indolent recurrence, transformation, and association with other primary cancers in patients treated for follicular lymphoma.
  • [MeSH-major] Diagnostic Imaging / methods. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Neoplasm, Residual. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / pathology. Prognosis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380942.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


18. Petridou ET, Sergentanis TN, Dessypris N, Vlachantoni IT, Tseleni-Balafouta S, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M, Mantzoros CS: Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. J Clin Oncol; 2009 Oct 20;27(30):5049-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study.
  • PURPOSE: To our knowledge, this is the first study exploring the association of childhood non-Hodgkin's lymphoma (NHL) with serum adiponectin and leptin levels in a nationwide case-control series.
  • In addition, expression of adiponectin receptors in NHL specimens was assessed, and the association between adipokines and childhood NHL survival and prognosis was examined.
  • PATIENTS AND METHODS: We studied 121 incident childhood (0 to 14 years) NHL cases registered in the Nationwide Registry for Childhood Hematological Malignancies (1996 to 2006) and an equal number of matched controls, for whom sociodemographic, lifestyle, prenatal characteristics, and fasting blood serums were collected.
  • Immunohistochemisty for adiponectin receptors expression was performed on commercially available adult NHL specimens (n = 30) and in a subset of childhood NHL cases (n = 6) that were available.
  • RESULTS: Higher serum adiponectin, but not leptin, levels were independently associated with childhood NHL (odds ratio, 1.82; 95% CI, 1.30 to 2.56), after adjusting for obesity and established risk factors.
  • Higher adiponectin levels at diagnosis were positively associated with relapse and poor survival, but hormone levels did not differ among NHL subtypes.
  • Adiponectin receptors 1 and 2 were present in 90% and 57% of adult samples and in 83% and 100% of childhood NHL samples, respectively.
  • CONCLUSION: Elevated serum adiponectin, but not leptin, levels are independently associated with childhood NHL and poor prognosis.
  • Adiponectin receptors are expressed in NHL, suggesting that adiponectin may represent not only a potential clinically significant diagnostic and prognostic marker but also a molecule that may be implicated in NHL pathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2006 Dec;25(4):537-41 [17310845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):308-13 [17301264.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1430-6 [17512191.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1031-7 [17653828.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Curr Pharm Des. 2007;13(36):3676-80 [18220805.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s858-66 [18265479.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):289-99 [18310295.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):3051-7 [18492759.001]
  • [Cites] Arch Dis Child. 2008 Dec;93(12):1027-32 [18676433.001]
  • [Cites] Mol Pathol. 1999 Oct;52(5):269-74 [10748876.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):875-82 [11777985.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Circulation. 2004 May 4;109(17):2046-9 [15096450.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):630-5 [15369797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1890-3 [1371884.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2169-74 [8400266.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):424-8 [8282815.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5499-505 [8968107.001]
  • [Cites] J Immunol. 1997 Jun 15;158(12):5596-602 [9190906.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:679-81 [9599716.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1229-37 [9777954.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 2):R136-42 [9887187.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Mar;62(3):366-71 [15730421.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1618-24 [15613407.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1625-31 [15613409.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5876-9 [16030165.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8481-6 [16714386.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2050-63 [16919770.001]
  • [Cites] Exp Oncol. 2006 Sep;28(3):241-4 [17080020.001]
  • [Cites] Diabetes Obes Metab. 2007 May;9(3):344-9 [17391161.001]
  • (PMID = 19738128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK058785; United States / NIDDK NIH HHS / DK / R01 DK058845; United States / NIDDK NIH HHS / DK / R56 DK058785; United States / NIDDK NIH HHS / DK / DK58845; United States / NIDDK NIH HHS / DK / DK58785; United States / NIDDK NIH HHS / DK / DK79929; United States / NIDDK NIH HHS / DK / R01 DK079929
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Leptin; 0 / Receptors, Adiponectin
  • [Other-IDs] NLM/ PMC2799057
  •  go-up   go-down


19. Pagès M, Girard-Herpe M, Rousset T, Pagès AM: [Non-Hodgkin's malignant lymphoma of the peripheral nervous system: clinicopathological correlations in ten patients]. Rev Neurol (Paris); 2005 Sep;161(8-9):823-8
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's malignant lymphoma of the peripheral nervous system: clinicopathological correlations in ten patients].
  • [Transliterated title] Lymphomes malins non Hodgkiniens du système nerveux périphérique. Corrélations anatomo-cliniques dans 10 observations.
  • INTRODUCTION: Identifying tumor infiltration or compression in patients with non-Hodgkin's malignant lymphoma presenting peripheral neuropathy can be a difficult task.
  • [MeSH-major] Lymphoma, Non-Hodgkin / physiopathology. Peripheral Nervous System Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / immunology. Cranial Nerve Diseases / epidemiology. Cranial Nerve Diseases / physiopathology. Electromyography. Female. Humans. Immunoglobulin A / immunology. Immunoglobulin G / immunology. Immunoglobulin M / immunology. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244564.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


20. Mukherji D, Pettengell R: Pixantrone maleate for non-Hodgkin's lymphoma. Drugs Today (Barc); 2009 Nov;45(11):797-805
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pixantrone maleate for non-Hodgkin's lymphoma.
  • The PIX301 phase III single-agent trial of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma randomized patients to receive either pixantrone or another single agent of the investigators' choice.
  • There is evidence that pixantrone is well tolerated when substituted for anthracyclines in combination regimens for aggressive non-Hodgkin's lymphoma with comparable rates of complete remission.
  • Pixantrone has also been used for the treatment of indolent non-Hodgkin's lymphomas and the combination of pixantrone and rituximab has been shown to be superior to rituximab alone in relapsed or refractory disease in the phase III PIX302 study.
  • On the basis of these data, the United States Food and Drug Administration is considering pixantrone for use in adult patients with relapsed or refractory aggressive and indolent non-Hodgkin's lymphoma on a fast-track basis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Isoquinolines / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Animals. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Topoisomerase II Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
  • (PMID = 20126672.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoquinolines; 0 / Topoisomerase II Inhibitors; F5SXN2KNMR / pixantrone
  • [Number-of-references] 31
  •  go-up   go-down


21. García Ortiz LM, Jaume Anselmi F, Ramírez Rivera J, Casiano Quiles W, Márquez Santiago R: Non-Hodgkin's lymphoma presenting as ulcerative colitis. Bol Asoc Med P R; 2006 Apr-Jun;98(2):140-3
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as ulcerative colitis.
  • High-grade Non-Hodgkin's lymphomas are very aggressive type of malignancies.
  • We report a high grade small B-cell (Burkitt's like) Non-Hodgkin's lymphoma that initially was considered and treated as ulcerative colitis without improvement or resolution of symptoms for nine months.
  • [MeSH-major] Colitis, Ulcerative / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606804.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


22. Mandal S, Varma K, Jain S: Cutaneous manifestations in non-Hodgkin's lymphoma. Acta Cytol; 2007 Nov-Dec;51(6):853-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous manifestations in non-Hodgkin's lymphoma.
  • OBJECTIVE: To examine and subtype cutaneous lymphoma specimens for diagnosis.
  • STUDY DESIGN: Aspiration smears from skin lesions and lymph nodes diagnosed as non-Hodgkin's lymphoma (NHL) on cytology in 6 cases over a period of 1 year were reviewed.
  • Two were follow-up cases of nodal lymphoma and were receiving chemotherapy, during which they developed skin lesions.
  • Cytologically, all cases were diagnosed as NHL.
  • CONCLUSION: Cutaneous lymphoma should always be considered in the presence of predominantly atypical lymphoid cells in smears from nodular and fungating skin lesions, even in the absence of a definitive clinical diagnosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077976.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Blick C, Abdelhadi S, Bailey D, Muneer A: Anaplastic, T-cell, non-Hodgkin's Lymphoma presenting with haematuria. ScientificWorldJournal; 2008;8:342-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic, T-cell, non-Hodgkin's Lymphoma presenting with haematuria.
  • Non-Hodgkin's lymphoma (NHL) represents about 3% of new cancer cases[1].
  • Bladder involvement has been found in approximately 3-13% of NHL patients when studied at postmortem[2].
  • T-cell lymphoma of the bladder is incredibly rare.
  • We describe a case of anaplastic, T-cell lymphoma presenting with haematuria and loin pain, with unilateral upper tract obstruction.
  • [MeSH-major] Hematuria / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379710.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Yu H, Hong XN, Li J, Peng LP, Ye L: [Prognostic factors of invasive non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 Jun;29(6):461-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of invasive non-Hodgkin's lymphoma].
  • OBJECTIVE: There is heterogeneity in non-Hodgkin's lymphoma.
  • The purpose of this study is to investigate the prognostic factors of invasive non-Hodgkin's lymphoma.
  • METHODS: From June 2002 to June 2006, 137 patients with invasive non-Hodgkin's lymphoma were treated by regular regimen consisting of radiotherapy and chemotherapy.
  • CONCLUSION: The overall survival of invasive non-Hodgkin's lymphoma treated with present combined therapy regimen has been improved greatly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / statistics & numerical data. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974284.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down


25. Pinkerton R: Continuing challenges in childhood non-Hodgkin's lymphoma. Br J Haematol; 2005 Aug;130(4):480-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuing challenges in childhood non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma in children includes a number of different pathological subtypes and, with improved diagnostic techniques and better understanding of the natural history of each type, treatment strategies have become more tumour-specific.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Patient Selection
  • [MeSH-minor] Adolescent. Adoptive Transfer. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Child. Humans. Lymphoproliferative Disorders / drug therapy. Positron-Emission Tomography. Risk Assessment. Rituximab. Stem Cell Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098061.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 75
  •  go-up   go-down


26. Cobzeanu MD, Costinescu V, Rusu CD, Mihailovici S, Grigoras M, Miron L, Paduraru D, Arama A: Laryngotracheal non-Hodgkin's lymphoma. Chirurgia (Bucur); 2010 Jan-Feb;105(1):131-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngotracheal non-Hodgkin's lymphoma.
  • The authors present an unexpected case of nonHodgkin Lymphoma localized in the subglottic larynx and upper cervical trachea.
  • The histopathologic exam of the surgical specimen showed malignant nonHodgkin lymphoma and the immunohistochemical profiles were evaluated in order to establish the therapeutic strategy including chemotherapy in the Department of Oncology.
  • CONCLUSIONS: Invasion of the subglottic larynx and trachea by lymphoma is an uncommon problem which can cause severe airway obstruction and requires multidisciplinary approach (ENT, pneumology, oncology/hematology).
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lymphoma, B-Cell / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Adult. Airway Obstruction / etiology. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Male. Radiotherapy, Adjuvant. Tracheotomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405695.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


27. Alexandrescu DT, Garino A, Brown-Balem KA, Wiernik PH: Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree. Leuk Lymphoma; 2006 Oct;47(10):2115-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree.
  • This study was conducted to determine whether anticipation occurs in families that exhibit both Hodgkin's (HD) and non-Hodgkin's (NHL) lymphoma in their pedigrees.
  • Nine published reports of multi-generational lymphoma and 33 previously unreported families with both lymphomas were analysed for evidence of anticipation.
  • Age at onset in studied cases was also compared with the HD and NHL series from the Surveillance Epidemiology and End Results (SEER) Program of the US National Cancer Institute.
  • Mean anticipation for parents with HD and children with NHL was -6.8 years (P = 0.01) for the unpublished and -14.4 years (P = 0.002) for the published families (overall anticipation -10.1 years).
  • Mean anticipation for parents with NHL and children with HD was -34.4 years (P < 0.0001) for the unpublished and -32.7 years (P < 0.0001) for the published families (overall anticipation -34.2 years, P < 0.0001).
  • The null hypothesis was also rejected for both the parents with HD/children with NHL group and the parents with NHL/children with HD group pairs (P < 0.0001).
  • Age at onset distributions were significantly different for all generations with HD or NHL when compared to the SEER population (P < 0.00001), except for the parents with NHL, which showed no difference.
  • In addition, this study reports four previously unpublished families with three generations of lymphoma in their pedigrees.
  • These data suggest that anticipation occurs in families that exhibit both HL and NHL and that both neoplasms may have a common genetic basis.
  • [MeSH-major] Age of Onset. Anticipation, Genetic. Hodgkin Disease / diagnosis. Hodgkin Disease / genetics. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Pedigree. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2015-6 [17071471.001]
  • (PMID = 17071485.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Fatnassi R, Bellara I: [Primary non-Hodgkin's lymphomas of the breast. Report of two cases]. J Gynecol Obstet Biol Reprod (Paris); 2005 Nov;34(7 Pt 1):721-4
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphomas of the breast. Report of two cases].
  • [Transliterated title] Les lymphomes malins non-hodgkiniens primitifs du sein: á propos de deux cas.
  • Non-hodgkin's lymphoma (NHL) represents 0.04 to 0.53% of all breast cancers.
  • We report two cases of primary non-hodgkin's lymphoma of the breast in two patients aged respectively 37 and 57 years.
  • The diagnosis of non-hodgkin's lymphoma was confirmed on histological examination of tumor biopsies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Mammography. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270012.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Safi S, Kassmaoui H, Hassikou H, Alami M, Homadi A, Tabache F, Baaj M, Hadri L: [Primary non-Hodgkin's lymphoma of the adrenals. A case report]. Ann Endocrinol (Paris); 2007 Jun;68(2-3):208-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the adrenals. A case report].
  • [Transliterated title] Lymphome malin non hodgkinien primitif de la surrénale. A propos d'un cas.
  • Bilateral primary non-Hodgkin's lymphoma (NHL) of the adrenals is uncommon.
  • We report a case of large diffuse B-cell adrenal lymphoma discovered in a 40-year-old woman presenting bilateral lumbar pain.
  • Percutaneous CT-guided biopsy of the adrenal and search for extension revealed primary bilateral adrenal lymphoma.
  • The diagnosis of primary adrenal non-Hodgkin lymphoma should be investigated in patients with a rapidly growing bilateral adrenal mass associated with adrenal insufficiency.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Prednisone / therapeutic use. Shock, Septic / etiology. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531185.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


30. Kuittinen T, Jantunen E, Vanninen E, Mussalo H, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, Hartikainen J: Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol; 2006 Aug;77(2):120-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
  • OBJECTIVES: Limited data are available on the cardiac effects of high-dose cyclophosphamide (CY) in patients with non-Hodgkin's lymphoma (NHL).
  • We prospectively assessed the cardiac effects of high-dose CY in 30 adult NHL patients receiving CY 6 g/m(2) as part of BEAC high-dose therapy (HDT).
  • CONCLUSIONS: Our findings suggest that high-dose CY results in acute, subclinical systolic dysfunction in NHL patients previously treated with anthracyclines.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / adverse effects. Heart / drug effects. Lymphoma, Non-Hodgkin / drug therapy. Peripheral Blood Stem Cell Transplantation. Postoperative Complications / chemically induced. Ventricular Dysfunction, Left / chemically induced
  • [MeSH-minor] Adult. Aged. Atrial Natriuretic Factor / blood. Biomarkers. Carmustine / administration & dosage. Carmustine / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gated Blood-Pool Imaging. Humans. Male. Middle Aged. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood. Postoperative Period. Prospective Studies. Protein Precursors / blood. Sensitivity and Specificity. Stroke Volume. Systole. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856907.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / N-terminal proatrial natriuretic peptide; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 04079A1RDZ / Cytarabine; 114471-18-0 / Natriuretic Peptide, Brain; 6PLQ3CP4P3 / Etoposide; 85637-73-6 / Atrial Natriuretic Factor; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine; BAEC protocol
  •  go-up   go-down


31. Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, Cormerais L, Gourdon F, Peigue-Lafeuille H, Travade P, Beytout J, Laurichesse H: [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003]. Med Mal Infect; 2006 Mar;36(3):157-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
  • [Transliterated title] Lymphomes non hodgkiniens et hodgkiniens et infection VIH: fréquence, pronostic et reconstitution immune sous trithérapie antirétrovirale; CHU de Clermont-Ferrand, 1991-2003.
  • OBJECTIVES: The authors had for aim to identify cases of non Hodgkin's (NHL) and Hodgkin's (HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of lymphoma-free patients under HAART.
  • RESULTS: Forty-one patients were included: 35 NHL and 6 HL giving a cumulative incidence rate estimate from 2.4% between 1991 and 1996 to 3.4% between 1997 and 2003 while other opportunistic diseases were decreasing.
  • A high proportion of aggressive and disseminated disease was observed among NHL cases.
  • Complete remission was achieved in 17 (49%) and 5 (83%) NHL and HL cases respectively.
  • The mean survival was 109+/-54 months and was correlated with CD4 cell count at lymphoma diagnosis (univariate analysis).
  • Immune restoration in lymphoma-free patients under HAART is poor.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV-1. Hodgkin Disease / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Cohort Studies. Female. France / epidemiology. Hospitals, University / statistics & numerical data. Humans. Incidence. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome


32. Sajid T, Intisar-ul-Haq, Haq I, Chaudhary AK: An obscure cause of leg edema, non-Hodgkin's lymphoma. J Coll Physicians Surg Pak; 2009 Apr;19(4):254-6
MedlinePlus Health Information. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An obscure cause of leg edema, non-Hodgkin's lymphoma.
  • Later, she turned out to be a case of non-Hodgkin's lymphoma.
  • This presentation is contrary to usual age and mode of presentation of non-Hodgkin's lymphoma.
  • [MeSH-major] Edema / etiology. Leg / pathology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Female. Humans. Risk Factors

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356344.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


33. Yeole BB: Trends in the incidence of Non-Hodgkin's lymphoma in India. Asian Pac J Cancer Prev; 2008 Jul-Sep;9(3):433-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of Non-Hodgkin's lymphoma in India.
  • Non-Hodgkin's lymphoma is the 11th most common cancer in terms of incidence.
  • It is not a single cancer, but rather a wide group of cancers (including entities such as Burkitt's lymphoma and diffuse large B-cell lymphoma), each with a district geographical distribution, development path, age profile and prognosis.
  • Non-Hodgkin's lymphoma is increasing in incidence world wide.
  • On this background, in this paper an attempt has been made to study the trends in Non-Hodgkin's lymphoma in various Indian populations in both sexes.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology. Female. Health Surveys. Humans. Incidence. India / epidemiology. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / epidemiology. Male. Middle Aged. Registries. Sex Distribution. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990016.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


34. Al-Maghrabi JA, Sawan AS, Kanaan HD: Hodgkin's lymphoma with exuberant granulomatous reaction. Saudi Med J; 2006 Dec;27(12):1905-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma with exuberant granulomatous reaction.
  • She presented to our institution one year after the initial diagnosis, and a new biopsy from the cervical lymph node revealed effacement of the whole node by marked non-necrotizing granulomatous reaction.
  • These findings confirmed the diagnosis of Hodgkin's lymphoma with remarkable granulomatous reaction that almost masked the malignant component.
  • [MeSH-major] Granuloma / etiology. Hodgkin Disease / complications. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Female. Humans. Neck

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143374.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


35. Crawshaw J, Sohaib SA, Wotherspoon A, Shepherd JH: Primary non-Hodgkin's lymphoma of the ovaries: imaging findings. Br J Radiol; 2007 Aug;80(956):e155-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the ovaries: imaging findings.
  • Primary ovarian lymphoma is very rare.
  • We report a case of primary ovarian Burkitt-type non-Hodgkin's lymphoma, describing the imaging appearance on ultrasound, CT and MRI, and review the literature.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Ovarian Neoplasms / diagnosis. Ovary / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762045.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 7
  •  go-up   go-down


36. Lahiani Ben Salah H, Daoud J: [Primary cervical epidural low-grade non-hodgkin's lymphoma: a case report and review of the literature]. Cancer Radiother; 2008 Dec;12(8):863-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cervical epidural low-grade non-hodgkin's lymphoma: a case report and review of the literature].
  • [Transliterated title] Le lymphome non-hodgkinien de bas grade épidural cervical primitif: à propos d'un cas et revue de la littérature.
  • Primary epidural cervical non-hodgkin's low-grade lymphomas is exceptional.
  • The histological study revealed a small cells lymphoma.
  • We review literature to describe epidemiological, clinical and therapeutic features with evolutive aspects in primary epidural non-hodgkin's lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565781.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


37. Mohapatra PR, Bhuniya S, Garg S, Dimri K, Janmeja AK: Endobronchial non-Hodgkin's lymphoma presenting as mass lesion. Indian J Chest Dis Allied Sci; 2009 Apr-Jun;51(2):107-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial non-Hodgkin's lymphoma presenting as mass lesion.
  • Endobronchial biopsy from the mass lesion yielded low grade B-cell non-Hodgkin's lymphoma.
  • This is one of the rarest presentation of non-Hodgkin's lymphoma.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Bronchoscopy. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445447.001).
  • [ISSN] 0377-9343
  • [Journal-full-title] The Indian journal of chest diseases & allied sciences
  • [ISO-abbreviation] Indian J Chest Dis Allied Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


38. De Roos AJ, Hartge P, Lubin JH, Colt JS, Davis S, Cerhan JR, Severson RK, Cozen W, Patterson DG Jr, Needham LL, Rothman N: Persistent organochlorine chemicals in plasma and risk of non-Hodgkin's lymphoma. Cancer Res; 2005 Dec 1;65(23):11214-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent organochlorine chemicals in plasma and risk of non-Hodgkin's lymphoma.
  • Polychlorinated biphenyls (PCB) have been suspected as possible contributors to increasing non-Hodgkin's lymphoma incidence during the latter half of the 20th century based on their toxicologic properties and provocative epidemiologic reports.
  • We investigated PCBs and other organochlorines and risk of non-Hodgkin's lymphoma in a population-based case-control study in the United States.
  • Risks of non-Hodgkin's lymphoma associated with each analyte were estimated using conditional logistic regression for the continuous measure, exposure quartiles, trend across quartile categories, and exposures above the 95th percentile.
  • Certain PCB congeners were associated with increased risk of non-Hodgkin's lymphoma, including coplanar PCBs 156, 180, and 194, with odds ratios for the highest versus lowest quartile ranging from 2.7 to 3.5, and significant trends.
  • Each of the furan congeners was associated with risk of non-Hodgkin's lymphoma, as were total furans, with 3.5-fold increased risk for the highest versus lowest quartile and a significant trend across quartiles (P = 0.006).
  • The toxic equivalency quotient (TEQ), a summed metric that weights congeners by their dioxin-like potency, was associated with non-Hodgkin's lymphoma, with 35% increased risk per 10 TEQ pg/g lipid (95% confidence interval, 1.02-1.79).
  • Our results add to existing literature, which suggests that exposure to organochlorines contributes to non-Hodgkin's lymphoma risk; these risks were most apparent for certain PCBs and furans.
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / chemically induced. Polychlorinated Biphenyls / blood. Polychlorinated Biphenyls / poisoning
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Dioxins / blood. Dioxins / poisoning. Female. Furans / blood. Furans / poisoning. Humans. Male. Middle Aged. Pesticides / blood. Pesticides / poisoning

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322272.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67008; United States / NCI NIH HHS / CN / N01-CN-67010; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / CP / Y1-CP-8028-02; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dioxins; 0 / Furans; 0 / Pesticides; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


39. Tsartsidze E, Betaneli M: Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma. Georgian Med News; 2006 May;(134):107-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate prognostic value of immunophenotype in aggressive Non-Hodgkin's lymphoma.
  • 87 patients with immunohistologically confirmed diagnosis of aggressive Non-Hodgkin's lymphoma according to the WHO classification (2001) were under observation.
  • T-cell phenotype should be considered as an independent factor that strongly influences the survival for patients with diagnosis of aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] B-Lymphocytes / immunology. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / mortality. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Humans. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783081.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


40. Planinc-Peraica A, Kolonić SO, Radić-Kristo D, Dominis M, Jaksić B: Serum immunoglobulins in non-Hodgkin's lymphoma patients. Coll Antropol; 2010 Jun;34(2):407-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum immunoglobulins in non-Hodgkin's lymphoma patients.
  • Serum proteins and immunoglobulin (Ig) findings in 119 non-Hodgkin's lymphoma (NHL) patients were analysed.
  • Out of them 96 (81%) patients had B non-Hodgkin lymphoma (B-NHL), and 23 (19%) T-NHL.
  • Indolent type of NHL was more frequent (77 patients, 65%), then aggressive type of NHL (42 patients, 35%).
  • The statistically significant association was not found between serum Ig concentration and lymphoma malignancy grade as well as between serum Ig concentration and immunologic origin of lymphoma.
  • T-NHL patients have more often IgA concentration level above or under normal values than B-NHL patients (p < 0.05).
  • [MeSH-major] Immunoglobulins / blood. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Blood Proteins / analysis. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Retrospective Studies. Serum Albumin / metabolism. Serum Globulins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698110.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 0 / Serum Albumin; 0 / Serum Globulins
  •  go-up   go-down


41. Bralić M, Stemberga V, Cuculić D, Coklo M, Bulić O, Grgurević E, Bosnar A: Primary non-Hodgkin's lymphoma of the humerus presenting as osteomyelitis. Coll Antropol; 2008 Oct;32 Suppl 2:229-31
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the humerus presenting as osteomyelitis.
  • We report a case of primary non-Hodgkin's lymphoma of the humerus that occurred in a 21-year-old male patient.
  • A biopsy was performed and the final pathologic diagnosis was a diffuse large B-cell lymphoma.
  • The patient was treated for lymphoma only with radiotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus. Lymphoma, Large B-Cell, Diffuse / pathology. Osteomyelitis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Errors. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138030.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


42. Roy S, Dobson P, Henry L: An isolated osteochondroma with underlying non-Hodgkin's lymphoma of bone. J Bone Joint Surg Br; 2005 Oct;87(10):1423-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An isolated osteochondroma with underlying non-Hodgkin's lymphoma of bone.
  • We report a case of an isolated osteochondroma which appeared benign on clinical and plain radiographic examination but routine histological analysis revealed non-Hodgkin's lymphoma in the underlying bone.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Osteochondroma / pathology
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Osteochondroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189321.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Batuecas Caletrío A, Gómez González JL, Muñoz Herrera A, Blanco Pérez P, Serradilla López JM, Gil Melcón M, Ocio San Miguel EM: [Non Hodgkin's lymphoma in the ENT field]. Acta Otorrinolaringol Esp; 2005 May;56(5):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in the ENT field].
  • [Transliterated title] Linfomas no Hodgkin en patología cérvico-facial.
  • OBJECTIVES: Non Hodgkin's lymphoma (NHL) is a frecuent tumor in the ENT field althougt there are not too many publications with a large number of patients.
  • PATIENTS AND METHODS: We have studied 300 patiens with NHL and analysed the head and neck affectation, the presence in Waldeyer's ring, the first symptoms and the stage of the disease.
  • CONCLUSION: There is an evident relationship between NHL and the Oto-Rhino-laringology area and it is necessary consider it in the differential diagnosis of head and neck adenopathies.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Otorhinolaryngologic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960125.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


44. Bliss A, Buriak S: Descriptive epidemiology of non-Hodgkin's lymphoma in Oklahoma: 1997-2003. J Okla State Med Assoc; 2008 Nov;101(11):262-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of non-Hodgkin's lymphoma in Oklahoma: 1997-2003.
  • OBJECTIVE: To describe the incidence of Non-Hodgkin's lymphoma in Oklahoma residents.
  • A non-significantly elevated SIR was found among American Indians (AI) when compared to Whites: 1.12 (0.78-1.18).
  • CONCLUSIONS: Further research is warranted to identify factors that may increase risk of development of NHL for American Indians in Oklahoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Continental Population Groups. Epidemiologic Studies. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Oklahoma / epidemiology. Registries. Risk Factors. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19113066.001).
  • [ISSN] 0030-1876
  • [Journal-full-title] The Journal of the Oklahoma State Medical Association
  • [ISO-abbreviation] J Okla State Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Tian H, Chen J, Wu Y, Li LL: [Efficacy of alternating triple therapy on relapsed or refractory non-Hodgkin's lymphoma]. Ai Zheng; 2008 Jun;27(6):633-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of alternating triple therapy on relapsed or refractory non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL) remains difficult.
  • This study was to evaluate the efficacy of alternating triple therapy (ATT), alternating administration of ASHAP, m-BACOD, and MINE regimens every 3 weeks, on relapsed or refractory NHL.
  • METHODS: Clinical data of 38 patients with relapsed or refractory NHL (28 relapsed NHL and 10 refractory NHL) treated with ATT were analyzed.
  • The response rate was 60.0% in B-cell lymphoma patients and 55.6% in T-cell lymphoma patients; it was 65.4% in the patients of <or=60 years old and 41.7% in the patients of >60 years old.
  • CONCLUSIONS: ATT is effective and well tolerated in patients with relapsed or refractory NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570739.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


46. Wei G, Yuping Z, Jun W, Bing Y, Qiaohua Z: CA125 expression in patients with non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jul;47(7):1322-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA125 expression in patients with non-Hodgkin's lymphoma.
  • The present study investigated the possible clinical significance of serum CA125 levels in patients with non-Hodgkin's lymphoma (NHL) and the mechanism of secretion.
  • Serum CA125 levels in 335 patients with NHL were measured by enzyme-linked immunosorbent assay.
  • The tissue CA125 expression in 22 patients with NHL was performed on paraffin section by immunohistochemical methods.
  • Our results suggested that serum CA125 levels could be an interesting tumor marker in NHL.
  • The immunohistochemical study suggested that CA125 appeared not to be secreted by lymphoma cells directly.
  • [MeSH-major] CA-125 Antigen / biosynthesis. CA-125 Antigen / blood. Gene Expression Regulation, Neoplastic. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Regression Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923563.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


47. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, Martini M, Larocca LM, Voso MT, Leone G: Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol; 2009 Aug;20(8):1408-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkin's lymphoma (HL), 63 with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkin's lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene.
  • RESULTS: Levels of circulating DNA in patients with HL, DLBCL, and mantle cell NHL were significantly higher than in controls (P < 0.01 for all).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465421.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / beta-Globins
  •  go-up   go-down


48. Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S: Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Oct 1;12(19):5622-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma.
  • Here, we investigated whether stromal incorporation of CD68(+) hemangiogenic cells and alpha-smooth muscle actin(+) (alpha-SMA(+)) stromal cells correlates with neoangiogenesis and progression in human non-Hodgkin's lymphoma subtypes.
  • EXPERIMENTAL DESIGN: Spatial localizations of vascular and stromal cells expressing CD34, VEGFR-1, alpha-SMA, and CD68 were examined by immunohistochemistry in 42 cases of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and compared with benign follicular hyperplasia.
  • Overall, there was no correlation between CD34(+) microvessel density and lymphoma histologic subtype.
  • CONCLUSIONS: Heightened stromal hemangiogenesis as marked by infiltration of proangiogenic VEGFR-1(+)CD68(+)VEGF-A(+) cells and their paracrine cross-talk with neovasculature appears to be a distinct feature of aggressive lymphoma, providing novel targets for antiangiogenic therapy, whereas alpha-SMA(+) stromal vascular network may be differentially targeted in CLL/SLL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Neovascularization, Pathologic / pathology. Stromal Cells / pathology
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Microcirculation. Middle Aged. Muscle, Smooth / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020964.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 075234; United States / NHLBI NIH HHS / HL / HL 59312; United States / NHLBI NIH HHS / HL / HL 67839; United States / NCRR NIH HHS / RR / K23 RR 016814
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


49. Akoum R, Brihi E, Saade M, Hanna T, Chahine G: Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma. J Cancer Res Ther; 2007 Jul-Sep;3(3):143-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma.
  • BACKGROUND: Abdominal irradiation, as a part of treatment, is often ignored in the management of refractory non-Hodgkin's lymphoma (NHL).
  • MATERIALS AND METHODS: 27 patients with intraabdominal lymphoma underwent salvage irradiation between 1982 and 2001.
  • Survival rates were significantly better for patients with refractory relapse compared to those with primary refractory lymphoma (P < 0.01).
  • CONCLUSION: Salvage radiotherapy for refractory abdominal NHL is a feasible alternative for both follicular and diffuse subtypes and may provide significant palliation and prolongation of survival.
  • It is less effective in patients with primary refractory NHL than in those with refractory relapsed NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Salvage Therapy
  • [MeSH-minor] Abdomen. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079576.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


50. Wu Y, Liu WL, Sun HY, Xu HZ: [Expression of P120ctn in non-Hodgkin's lymphoma and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun;14(3):508-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of P120ctn in non-Hodgkin's lymphoma and its significance].
  • To evaluate the expression of P120ctn in non-Hodgkin's lymphoma (NHL) and to explore its clinical significance, immunohistochemistry stain method was applied to comparatively investigate the protein expression of P120ctn in paraffin-embedded lymph node tissue slices from 40 cases of NHL and 10 cases of reactive hyperplasia of lymph node.
  • The results showed that P120ctn was not detected in reactive hyperplasia of lymph node, but was detected in 55% (22/40) cases of NHL.
  • P120ctn expression increased with the tumor malignancy of NHL, there was a significant difference between the expression rates of P120ctn in low grade (16.7%, 2/12) and intermediate to high grade malignant (71.4%, 20/28) NHL (P < 0.001).
  • Moreover, P120ctn was also detected in vascular endothelial cells of NHL.
  • It is concluded that the level of P120ctn expression is closely related to the malignant grade of NHL, it suggests that P120ctn possibly plays an important role in the malignant proliferation of lymphoma with a certain significance in diagnosis and therapy of lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800931.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Phosphoproteins; 0 / delta catenin
  •  go-up   go-down


51. Wang T, Gui W, Shen Q: Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis. Med Oncol; 2010 Sep;27(3):661-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis.
  • The objective is to investigate the association between pathological type and clinical features, response to treatment and prognosis of primary gastrointestinal Non-Hodgkin's lymphoma (PGINHL).
  • In 115 (92.7%) patients of B-cell lymphoma, mucosa-associated lymphoid tissue lymphoma (MALToma) and diffuse large B-cell lymphoma (DLBCL) were 55 and 50 patients, respectively.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prognosis. Proportional Hazards Models. Risk. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1929-34 [10206316.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):405-7 [15101733.001]
  • [Cites] Endoscopy. 2004 Nov;36(11):1022-4 [15520925.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):339-44 [15101721.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Am Surg. 2008 Mar;74(3):214-6 [18376684.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1093-103 [10725618.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1751-7 [14630680.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):349-52 [15958057.001]
  • [Cites] Intern Med. 2006;45(6):405-9 [16617193.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):1992-9 [18647965.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 2006;45(2):202-9 [16546867.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2008 Feb;28(2):243-5 [18250053.001]
  • [Cites] J Pathol. 2005 Jan;205(2):255-74 [15643667.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 19565363.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


52. Hardell L, Eriksson M, Carlberg M, Sundström C, Mild KH: Use of cellular or cordless telephones and the risk for non-Hodgkin's lymphoma. Int Arch Occup Environ Health; 2005 Sep;78(8):625-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cellular or cordless telephones and the risk for non-Hodgkin's lymphoma.
  • OBJECTIVES: To evaluate the use of cellular and cordless telephones as the risk factor for non-Hodgkin's lymphoma (NHL).
  • NHL of the B-cell type was not associated with the use of cellular or cordless telephones.
  • Regarding T-cell NHL and >5 year latency period, the use of analogue cellular phones yielded: odds ratio (OR) = 1.46, 95%; confidence interval (CI) = 0.58-3.70, digital: OR=1.92, 95%; CI=0.77-4.80 and cordless phones: OR=2.47; CI=1.09-5.60.
  • The corresponding results for certain, e.g. cutaneous and leukaemia, T-cell lymphoma for analogue phones were: OR=3.41, 95%; CI=0.78-15.0, digital: OR=6.12, 95%; CI=1.26-29.7 and cordless phones: OR=5.48, 95%; CI=1.26-23.9.
  • CONCLUSIONS: The results indicate an association between T-cell NHL and the use of cellular and cordless telephones, however based on low numbers and must be interpreted with caution.
  • Regarding B-cell NHL no association was found.
  • [MeSH-major] Cell Phones / statistics & numerical data. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Microwaves / adverse effects. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Res. 1999;11(11-12):539-44 [10905566.001]
  • [Cites] Radiat Res. 1997 May;147(5):631-40 [9146709.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):619-29 [11697490.001]
  • [Cites] Mutat Res. 2000 Dec 20;472(1-2):51-8 [11113697.001]
  • [Cites] Radiat Res. 2002 Sep;158(3):357-64 [12175314.001]
  • [Cites] Bioelectromagnetics. 2002 Feb;23(2):113-26 [11835258.001]
  • [Cites] Mutat Res. 1992 Mar;281(3):181-6 [1371840.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):399-407 [12527940.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):324-32 [14603534.001]
  • [Cites] Occup Environ Med. 2005 Jun;62(6):390-4 [15901886.001]
  • [Cites] Bioelectromagnetics. 1993;14(6):495-501 [8297394.001]
  • [Cites] Environ Health Perspect. 2003 Nov;111(14):1704-6 [14594618.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1353-60 [10189142.001]
  • [Cites] Bioelectromagnetics. 1992;13(6):469-96 [1482413.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2004 Sep-Oct;7(5):351-84 [15371240.001]
  • [Cites] Bioelectromagnetics. 2003 Feb;24(2):82-90 [12524674.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):441-5 [10811571.001]
  • [Cites] Oncol Res. 1998;10(1):1-5 [9613451.001]
  • [Cites] Int J Mol Med. 2003 Jul;12(1):67-72 [12792811.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):240-4 [9242800.001]
  • (PMID = 16001209.001).
  • [ISSN] 0340-0131
  • [Journal-full-title] International archives of occupational and environmental health
  • [ISO-abbreviation] Int Arch Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


53. Mileti J, Mileti L, Kaeding C: Non-Hodgkin's lymphoma of the knee diagnosed by arthroscopy. Arthroscopy; 2007 Apr;23(4):447.e1-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the knee diagnosed by arthroscopy.
  • We report a case of non-Hodgkin's lymphoma of the knee diagnosed by arthroscopy in an otherwise healthy, active 31-year-old woman.
  • [MeSH-major] Arthroscopy / methods. Knee Joint. Lymphoma, Non-Hodgkin / diagnosis. Synovitis / diagnosis
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Risk Assessment. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418346.001).
  • [ISSN] 1526-3231
  • [Journal-full-title] Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association
  • [ISO-abbreviation] Arthroscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Chang ET, Bälter KM, Torrång A, Smedby KE, Melbye M, Sundström C, Glimelius B, Adami HO: Nutrient intake and risk of non-Hodgkin's lymphoma. Am J Epidemiol; 2006 Dec 15;164(12):1222-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutrient intake and risk of non-Hodgkin's lymphoma.
  • The mechanisms through which diet may influence the development of non-Hodgkin's lymphoma (NHL) are unclear but can be better understood by examining associations between nutrient consumption and NHL risk.
  • Between 2000 and 2002, 591 NHL cases and 460 population-based controls in Sweden completed a semiquantitative food frequency questionnaire.
  • Dietary intake of most macronutrients was not associated with risk of NHL or its common subtypes.
  • Consumption of omega-3 or marine fatty acids was associated with decreased risk of NHL and chronic lymphocytic lymphoma, and dietary fiber was associated with lower risk of all subtypes examined.
  • When the highest and the lowest quartiles of marine fat intake were compared, the odds ratio for NHL risk was 0.6 (95% confidence interval: 0.4, 0.9), ptrend=0.03; for dietary fiber intake, the corresponding odds ratio was 0.5 (95% confidence interval: 0.3, 0.7), ptrend<0.001.
  • Dietary consumption of beta-carotene or alpha-tocopherol was associated with lower NHL risk, whereas intake of calcium or retinol was associated with increased NHL risk.
  • Nutrients that affect inflammation, vitamin D activity, oxidative DNA damage, or DNA methylation may be associated with risk of NHL.
  • [MeSH-major] Diet. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Diet Surveys. Dietary Fats / administration & dosage. Dietary Fiber / administration & dosage. Energy Intake. Female. Humans. Male. Middle Aged. Sweden / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Epidemiol. 2007 Apr 1;165(7):848
  • (PMID = 17005624.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069269-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  •  go-up   go-down


55. Nishimori H, Fujii N, Maeda Y, Matsuoka K, Takenaka K, Shinagawa K, Ikeda K, Matsuo K, Harada M, Tanimoto M: Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma. Anticancer Res; 2009 May;29(5):1749-54
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
  • BACKGROUND: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined.
  • PATIENTS AND METHODS: Thirty-four patients with refractory or relapsed NHL were treated with IDEA.
  • CONCLUSION: IDEA is an effective second-line chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytarabine / adverse effects. Cytarabine / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Feasibility Studies. Female. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Male. Middle Aged. Recurrence. Retrospective Studies. Salvage Therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443398.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; UM20QQM95Y / Ifosfamide; G-IDEA protocol
  •  go-up   go-down


56. Zhang MZ, Zang WP, Song M, Geng L, Li X, Wang RL: [Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma]. Ai Zheng; 2008 Apr;27(4):435-7
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: There is no standard salvage regimen for patients with relapsed and refractory non-Hodgkin's lymphoma (NHL) at present.
  • This study was to evaluate the efficacy of DACE regimen, as a salvage regimen, on relapsed and refractory NHL, and observe the adverse events.
  • METHODS: From May 2001 to May 2006, 61 patients with relapsed and refractory NHL received chemotherapy of DACE regimen: intravenous infusion of cisplatin (20 mg/m(2)) on Days 1-5, etoposide (100 mg) on Days 1-5, cytarabine (150 mg) on Days 1-3, and dexamethone (15 mg/m(2)) on Days 1-5; repeated every 3 weeks.
  • CONCLUSION: DACE regimen is an effective salvage regimen in treating patients with relapsed and refractory NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423133.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Steinsson K, Nived O, Sturfelt G, St Pierre Y, Clarke A: Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis; 2005 Oct;64(10):1507-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in systemic lupus erythematosus.
  • BACKGROUND: Recent evidence supports an association between systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL).
  • OBJECTIVES: To describe demographic factors, subtypes, and survival of patients with SLE who develop NHL.
  • For the NHL cases ascertained, descriptive statistics were calculated, and NHL subtype frequency and median survival time of patients determined.
  • RESULTS: 42 cases of NHL occurred in the patients with SLE during the 76,948 patient-years of observation.
  • The median age of patients at NHL diagnosis was 57 years.
  • Thirty six (86%) of the 42 patients developing NHL were women, reflecting the female predominance of the cohort.
  • In the patients, aggressive histological subtypes appeared to predominate, with the most commonly identified NHL subtype being diffuse large B cell (11 out of 21 cases for which histological subtype was available).
  • Twenty two of the patients had died a median of 1.2 years after lymphoma diagnosis.
  • CONCLUSIONS: These data suggest aggressive disease in patients with SLE who develop NHL.
  • Continuing work should provide further insight into the patterns of presentation, prognosis, and aetiology of NHL in SLE.

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162903.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR 02138; United States / NIAMS NIH HHS / AR / AR 48098
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1755239
  •  go-up   go-down


58. Hauswirth AW, Skrabs C, Schützinger C, Raderer M, Chott A, Valent P, Lechner K, Jäger U: Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica; 2008 Mar;93(3):447-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune thrombocytopenia in non-Hodgkin's lymphomas.
  • Autoimmune thrombocytopenia is a common immunehematologic complication in non-Hodgkin's lymphomas and may complicate the treatment.
  • We analyzed an original series from our institute as well as published cases of non-Hodgkin's lymphomas (excluding chronic lymphocytic leukemia) associated with autoimmune thrombocytopenia with regard to demographic factors, prevalence in non-Hodgkin's lymphoma subtypes and treatment outcome.
  • Half of the cases occurred prior to diagnosis of lymphoma.
  • Chemotherapy is the best treatment in many non-Hodgkin's lymphomas patients with autoimmune thrombocytopenia compared with standard treatment of autoimmune thrombocytopenia.
  • Splenectomy is effective in splenic marginal zone lymphoma.
  • Autoimmune thrombocytopenia in patients with non-Hodgkin's lymphomas is potentially life-threatening and difficult to treat.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Purpura, Thrombocytopenic, Idiopathic / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Comorbidity. Female. Humans. Leukemia, Hairy Cell / drug therapy. Leukemia, Hairy Cell / epidemiology. Male. Middle Aged. Multiple Myeloma / epidemiology. Peripheral Blood Stem Cell Transplantation. Postoperative Complications / epidemiology. Prevalence. Splenectomy. Treatment Outcome. Waldenstrom Macroglobulinemia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287133.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, Caldwell CW: Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis; 2007 Jan;28(1):60-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) is a group of malignancies with heterogeneous genetic and epigenetic alterations.
  • Discovery of molecular markers that better define NHL should improve diagnosis, prognosis and understanding of the biology.
  • We developed a CpG island DNA microarray for discovery of aberrant methylation targets in cancer, and now apply this method to examine NHL cell lines and primary tumors.
  • This methylation profiling revealed differential patterns in six cell lines originating from different subtypes of NHL.
  • Methylation of 6 of these genes was then further examined in 75 primary NHL specimens composed of four subtypes representing different stages of maturation.
  • This promoter hypermethylation inversely correlated with DLC-1 gene expression in primary NHL samples.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. CpG Islands. GTPase-Activating Proteins. Gene Expression Profiling. Genome, Human. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Microarray Analysis. Middle Aged. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16774933.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA097880; United States / NCI NIH HHS / CA / CA100055; United States / NCI NIH HHS / CA / P50 CA097274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DLC1 protein, human; 0 / GTPase-Activating Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


60. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol; 2008 Nov 10;26(32):5165-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.
  • PURPOSE: To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL).
  • Transformed lymphoma was defined as the development of aggressive non-Hodgkin's lymphoma (NHL) in patients with FL.
  • Factors present at the time of initial diagnosis of indolent NHL and at transformation were analyzed for their impact on risk of transformation and subsequent outcome.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lymphoma, Follicular / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Biopsy. British Columbia / epidemiology. Disease Progression. Female. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Population Surveillance. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2008 Oct 20;26(30):4952-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • PURPOSE: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy.
  • Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL).
  • We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.
  • The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL.
  • CONCLUSION: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Prospective Studies. Remission Induction


62. van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA: Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica; 2005 May;90(5):661-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost determinants in aggressive non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: The 5 factors of the International Prognostic Index (IPI) for aggressive non Hodgkin's lymphoma (NHL) age, disease stage, serum lactate dehydrogenase (LDH), performance status, number of extranodal sites) are validated predictors of a patient's survival.
  • DESIGN AND METHODS: Chart data for 374 patients with newly diagnosed stage II-IV aggressive NHL treated between 1993-2001 with CHOP chemotherapy were used.
  • Regression analyses and non-parametric bootstrap tests were performed to determine the significance of prognostic factors.
  • The detailed information presented in this paper is of value for those who need to make cost-effectiveness estimations in NHL, which is a relevant topic, given new treatment modalities that are emerging.
  • [MeSH-major] Health Care Costs. Lymphoma, Non-Hodgkin / economics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / economics. Child. Combined Modality Therapy / economics. Cost-Benefit Analysis. Costs and Cost Analysis. Drug Costs. Female. Fever / epidemiology. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / economics. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Proteins / blood. Netherlands / epidemiology. Prognosis. Radiotherapy, Adjuvant / economics. Retrospective Studies. Risk Factors. Severity of Illness Index. Survival Analysis. Sweating. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921381.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


63. Colt JS, Davis S, Severson RK, Lynch CF, Cozen W, Camann D, Engels EA, Blair A, Hartge P: Residential insecticide use and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):251-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential insecticide use and risk of non-Hodgkin's lymphoma.
  • Previous studies have linked non-Hodgkin's lymphoma (NHL) with occupational exposure to insecticides, but residential use is largely unexplored.
  • In this population-based case-control study, we examined NHL risk and use of insecticides in the home and garden.
  • We identified NHL cases, uninfected with HIV, diagnosed between 1998 and 2000 among women and men ages 20 to 74 years in Iowa and the metropolitan areas of Los Angeles, Detroit, and Seattle.
  • People whose homes were treated for termites had elevated NHL risk (odds ratio, 1.3; 95% confidence interval, 1.0-1.6).
  • We concluded that chlordane treatment of homes for termites may increase residents' NHL risk.
  • [MeSH-major] Chlordan / toxicity. Environmental Exposure / adverse effects. Environmental Pollutants / toxicity. Insecticides / toxicity. Lymphoma, Non-Hodgkin / chemically induced
  • [MeSH-minor] Adult. Aged. Animals. Case-Control Studies. Dust / analysis. Female. Floors and Floorcoverings. Humans. Interviews as Topic. Isoptera. Male. Middle Aged. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492912.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67008; United States / NCI NIH HHS / CN / N01-CN-67010; United States / NCI NIH HHS / CP / N01-CP-19114; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67009; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dust; 0 / Environmental Pollutants; 0 / Insecticides; 12789-03-6 / Chlordan
  •  go-up   go-down


64. Bhurgri Y, Pervez S, Bhurgri A, Faridi N, Usman A, Kazi LA, Ahmed R, Kayani N, Hasan SH: Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002. Asian Pac J Cancer Prev; 2005 Jul-Sep;6(3):364-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002.
  • This first population-based study of non- Hodgkin lymphoma (NHL) from any region in Pakistan, provides an overview of the incidence pattern and time trends in Karachi and generates hypotheses for future experimental research.
  • Epidemiological data for 429 incident (1(st) Jan 1995 to 31(st) Dec 2002), microscopically verified nodal and extra-nodal NHL cases, registered at the Karachi Cancer Registry (KCR) for Karachi South, were reviewed.
  • A gradual increase in the annual incidence was observed during the study period, with NHL incidence rate increasing in 2002 to 8.4/100,000 in men and 6.5/100,000 in women, almost double the 1995 rates.
  • NHL affected all age groups in both genders and for each group the ASIR was higher among men than women, with an overall gender ratio of 1.9.
  • The adult to childhood ratios were 8.6 (M) and 10.7 (F).
  • B-cell NHL comprised 81.0% of NHL in males and 87.3% in females.
  • One fourth of the NHL cases were extra-nodal, the largest group was of gastrointestinal origin (54.1% M, 38.5% F).
  • Children and adolescents were at the highest risk of developing NHL, especially the 5-9 year olds, in both genders.
  • The incidence rates of NHL registered in Karachi South are likely to be a reflection of non-AIDS-associated NHL.
  • Estimated HIV/AIDS incidence was too low during the study period in this population to have an impact on NHL incidence.
  • The preponderance of low and intermediate grade lymphomas, paucity of central nervous system NHL and a higher childhood NHL component support this hypothesis.
  • NHL correlation with HIV/AIDS status and studies identifying risk factors of non- HIV/AIDS associated NHL (childhood viral infections, Hepatitis C virus, and Helicobacter pylori) are potential areas for future experimental and epidemiological research.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Epidemiologic Studies. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Pakistan / epidemiology. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236001.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


65. Nogovà L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):60-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin's lymphoma.
  • Lymphocyte-predominant Hodgkin's lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • Treatment of LPHL patients using standard Hodgkin's lymphoma protocols leads to complete remission in more than 95% of patients.
  • IF-RT seems to be emerging as a treatment of choice for patients with stage IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer, have adopted IF-RT as the treatment of choice for these patients.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Histiocytes / pathology. Humans. Lymphocytes / pathology. Neoplasm Staging. Patient Selection. Prognosis. Radiotherapy Dosage. Remission Induction. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Histopathology. 1990 Feb;16(2):157-65 [2323737.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):559-65 [8573534.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):99-106 [3791150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):377-83 [12416895.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7 [12972802.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1903-10 [14738141.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Feb;17(1):47-53 [15714929.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • (PMID = 20425333.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 25
  •  go-up   go-down


66. Bonnet C, Beguin Y, Fassotte MF, Seidel L, Luyckx F, Fillet G: Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol; 2007 May;78(5):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
  • BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome.
  • PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis.
  • RESULTS: CA125 serum levels were elevated in 34% of the patients, including 19% of patients with aggressive NHL, 45% of patients with indolent NHL, and 29% of patients with HD.
  • CONCLUSION: While CA125 serum level correlates significantly with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic markers in the management of patients with NHL or HD.
  • [MeSH-major] CA-125 Antigen / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419741.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


67. Willett EV, Skibola CF, Adamson P, Skibola DR, Morgan GJ, Smith MT, Roman E: Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer; 2005 Oct 03;93(7):811-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms.
  • A population-based case-control study of lymphomas in England collected height and weight details from 699 non-Hodgkin's lymphoma (NHL) cases and 914 controls.
  • Obesity, defined as a body mass index (BMI) over 30 kg m(-2) at five years before diagnosis,, was associated with an increased risk of NHL (OR = 1.5, 95% CI 1.1-2.1).
  • The excess was most pronounced for diffuse large B-cell lymphoma (OR = 1.9, 95% CI 1.3-2.8).
  • Genetic variants in the leptin (LEP 19G > A, LEP -2548G > A) and leptin receptor genes (LEPR 223Q > R), previously shown to modulate NHL risk, as well as a polymorphism in the energy regulatory gene adiponectin (APM1 276G>T), were investigated.
  • Findings varied with leptin genotype, the risks being decreased with LEP 19AA (OR = 0.7, 95% CI 0.5-1.0) and increased with LEP -2548GA (OR = 1.3, 95% CI 1.0-1.7) and -2548AA (OR = 1.4, 95% CI 1.0-1.9), particularly for follicular lymphoma.
  • [MeSH-major] Homeostasis / genetics. Lymphoma, Non-Hodgkin / genetics. Obesity / complications. Polymorphism, Genetic
  • [MeSH-minor] Adolescent. Adult. Base Sequence. Case-Control Studies. DNA Primers. Energy Metabolism. Humans. Leptin / genetics. Middle Aged. Receptors, Cell Surface / genetics. Receptors, Leptin

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nutr. 2002 Oct;41(5):210-21 [12395215.001]
  • [Cites] Am J Epidemiol. 2002 Sep 15;156(6):527-35 [12226000.001]
  • [Cites] J Biosoc Sci. 2003 Apr;35(2):263-85 [12664962.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Am J Epidemiol. 2004 Feb 1;159(3):259-68 [14742286.001]
  • [Cites] Eur J Hum Genet. 2004 Mar;12(3):199-205 [14673476.001]
  • [Cites] Diabetes. 2004 Apr;53(4):1150-7 [15047634.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S41-7 [15202524.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):220-30 [15197684.001]
  • [Cites] Am J Epidemiol. 2004 Sep 15;160(6):566-75 [15353417.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):771-80 [15456990.001]
  • [Cites] J Natl Cancer Inst. 1978 Jan;60(1):89-92 [272469.001]
  • [Cites] J Natl Cancer Inst. 1985 Jan;74(1):43-51 [3855486.001]
  • [Cites] Leuk Res. 1989;13(6):465-72 [2770331.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):275-9 [2303293.001]
  • [Cites] World Health Organ Tech Rep Ser. 1995;854:1-452 [8594834.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):869-76 [9175732.001]
  • [Cites] Diabetes. 1998 Mar;47(3):487-9 [9519759.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Mar;22(3):200-5 [9539186.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3239-42 [9745435.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] FEBS Lett. 2005 Jan 17;579(2):295-301 [15642335.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):210-8 [15687364.001]
  • [Cites] Nat Rev Genet. 2005 Mar;6(3):221-34 [15703762.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1751-8 [10528026.001]
  • [Cites] Ann Hum Genet. 1999 May;63(Pt 3):227-34 [10738535.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3126-31 [10999797.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3589-91 [11061506.001]
  • [Cites] Diabetes. 2000 Dec;49(12):2196-200 [11118025.001]
  • [Cites] World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253 [11234459.001]
  • [Cites] Ann Hum Genet. 2000 Sep;64(Pt 5):391-4 [11281277.001]
  • [Cites] Hum Genet. 2001 Mar;108(3):233-6 [11354636.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3227-32 [11443193.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4434-9 [11549688.001]
  • [Cites] Diabetes. 2002 Feb;51(2):536-40 [11812766.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Diabetes. 2002 Jul;51(7):2306-12 [12086965.001]
  • [Cites] Obes Rev. 2001 May;2(2):131-40 [12119664.001]
  • [Cites] Horm Metab Res. 2002 Jul;34(7):355-9 [12189581.001]
  • [Cites] Obes Res. 2003 Mar;11(3):377-86 [12634434.001]
  • (PMID = 16160698.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / R01-CA104862
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin
  • [Other-IDs] NLM/ PMC2361643
  •  go-up   go-down


68. Krawczuk-Rybak M, Solarz E, Gadomski J, Matysiak M, Wołczyński S: [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):623-30
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood].
  • AIM: To investigate testicular function (spermato- and steroidogenesis) in adolescents and young men cured of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • MATERIAL AND METHODS: In thirty one patients cured of HL 5.9 +/-3.3 years ago and sixteen--cured of NHL before 5.44y +/-2.9 and in twenty one healthy men, we measured serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone using immunoenzymatic methods and inhibin B (RIA method).
  • Patients with NHL and HL in clinical stage I and IIb, presented normal values of all analyzed parameters.
  • 2. The treatment for NHL essentially does not have a gonadotoxic effect.
  • [MeSH-major] Combined Modality Therapy / adverse effects. Gonadotropins, Pituitary / blood. Hodgkin Disease / therapy. Infertility, Male / etiology. Lymphoma, Non-Hodgkin / therapy. Spermatogenesis / drug effects. Spermatogenesis / radiation effects
  • [MeSH-minor] Adolescent. Adult. Child. Enzyme-Linked Immunosorbent Assay. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Male. Neoplasm Staging. Testicular Diseases / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317893.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


69. Sanna G, Lorizzo K, Rotmensz N, Bagnardi V, Cinieri S, Colleoni M, Nolè F, Goldhirsch A: Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol; 2007 Feb;18(2):288-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
  • BACKGROUND: Better therapeutic approaches for patients with Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) resulted in high cure rates, at cost of serious late side effects.
  • MATERIALS AND METHODS: Fifty-three women treated for primary BC with previous history of malignant lymphoma were identified in our institution, 35 with HD (66%), 18 (34%) with NHL.
  • A comparison group was randomly selected from our database matching for each patient with previous lymphoma, two patients with primary BC (rate 1 : 2) for age, stage (pathological tumour size [pT] status and nodal status), year of diagnosis, and estrogen and progesterone status (positive versus negative).
  • Considering these variables, no significant differences were observed between the two groups with the exception of Ki-67, which was found higher in those with previous HD or NHL (65% versus 49%, respectively, P = 0.0526, borderline significant).
  • However, regarding patients with node-positive disease (14 versus 35 patients), five patients in the lymphoma group (36%), compared with 24 (69%) in the matched group received anthracycline-based therapy (P = 0.0345).
  • CONCLUSIONS: Previous history of malignant lymphoma is a negative prognostic factor for women diagnosed subsequently with BC.


70. Brenner H, Gondos A, Pulte D: Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010. Oncologist; 2009 Aug;14(8):806-13
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010.
  • Available long-term survival figures for patients with Hodgkin's lymphoma (HL) from population-based cancer registries mostly refer to patients diagnosed in the 1980s and 1990s, and do not reflect recent progress in and spread of effective therapy at the population level.
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Aged. Cohort Studies. Databases, Factual. Humans. Middle Aged. Prognosis. Survival Analysis. Survivors. United States / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648314.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Asfour IA, El-Tehewi MM, Ahmed MH, Abdel-Sattar MA, Moustafa NN, Hegab HM, Fathey OM: High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma. Biol Trace Elem Res; 2009 Mar;127(3):200-10
Hazardous Substances Data Bank. SODIUM SELENITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma.
  • The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the apoptosis of lymphoma cells in patients with non-Hodgkin's lymphoma (NHL).
  • Forty patients with newly diagnosed NHL were randomly divided into two groups.
  • Flow cytometry was used for monitoring of lymphoma cells apoptosis at the time of diagnosis and after therapy in the two groups.
  • Sodium selenite administration resulted in significant increase in percentage of apoptotic lymphoma cells after therapy in group II (78.9 +/- 13.3% versus 58.9 +/- 18.9%, p < 0.05).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Apoptosis. Lymphoma, Non-Hodgkin / drug therapy. Sodium Selenite / administration & dosage
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953506.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; HIW548RQ3W / Sodium Selenite
  •  go-up   go-down


72. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF: Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol; 2006 May;17 Suppl 4:iv25-30
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
  • We have treated 75 transplant-eligible patients with relapsed or refractory lymphoma using an outpatient-based fractionated regimen of ifosfamide, carboplatin and etoposide (ICE) for both salvage and stem cell mobilisation.
  • Patients included DLBC (n = 33), follicular (n = 23), NK/T-cell (n = 3), mantle cell (n = 3) and Hodgkin's lymphoma (n = 13).
  • Most patients with indolent lymphoma also received rituximab.
  • Non-haematological toxicities included grade 1/2 CNS toxicity in four patients, cardiac toxicity in two, reversible renal impairment and haematuria in one each.
  • These data confirm the efficacy and tolerability of outpatient fractionated ICE as both a salvage and mobilisation regimen in relapsed/refractory lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702181.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


73. Kiresi DA, Kivrak AS, Ecirli S, Toy H: Secondary breast, pancreatic, and renal involvement with non-Hodgkin's lymphoma: Imaging findings. Breast; 2006 Feb;15(1):106-10
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary breast, pancreatic, and renal involvement with non-Hodgkin's lymphoma: Imaging findings.
  • The radiologic features in a patient with breast, pancreatic, and renal non-Hodgkin's lymphoma are presented in this paper.
  • Although diagnosis of lymphoma is based on histologic criteria, radiologic techniques may be helpful in the evaluation and follow-up of masses in patients with lymphoma.
  • [MeSH-major] Breast Neoplasms / pathology. Kidney Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473741.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


74. Liu A, Takakuwa T, Fujita S, Luo WJ, Tresnasari K, Van den Berg A, Poppema S, Aozasa K: ATR alterations in Hodgkin's lymphoma. Oncol Rep; 2008 Apr;19(4):999-1005
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATR alterations in Hodgkin's lymphoma.
  • Hodgkin's lymphoma (HL) is characterized by the presence of neoplastic Hodgkin and Reed-Sternberg cells (HRSC) in a background of inflammatory cells.
  • [MeSH-major] Cell Cycle Proteins / genetics. Hodgkin Disease / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adult. Aged. Ataxia Telangiectasia Mutated Proteins. Cell Line, Tumor. DNA Breaks. DNA Repair. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357388.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


75. Saatci AO, Arikan G, Ozcan MA, Ozkal S, Kargi A, Undar B: Indocyanine green angiographic features of systemic non-Hodgkin's lymphoma and bilateral choroidal involvement. Ophthalmic Surg Lasers Imaging; 2006 May-Jun;37(3):236-9
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indocyanine green angiographic features of systemic non-Hodgkin's lymphoma and bilateral choroidal involvement.
  • A 35-year-old man with systemic non-Hodgkin's lymphoma and bilateral choroidal involvement is described.
  • Indocyanine green angiography depicts choroidal involvement much better than fluorescein angiography and seems to be superior in diagnosing and monitoring patients with systemic non-Hodgkin's lymphoma and choroidal involvement.
  • [MeSH-major] Choroid Neoplasms / diagnosis. Coloring Agents. Fluorescein Angiography. Indocyanine Green. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16749262.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


76. Jacobsen E, LaCasce A: Update on the therapy of highly aggressive non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2006 Jul;6(7):699-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
  • This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma. Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Child. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805709.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 95
  •  go-up   go-down


77. Kiserud CE, Loge JH, Fosså A, Holte H, Cvancarova M, Fosså SD: Mortality is persistently increased in Hodgkin's lymphoma survivors. Eur J Cancer; 2010 Jun;46(9):1632-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality is persistently increased in Hodgkin's lymphoma survivors.
  • Aims of this study were to examine mortality and causes of death in Hodgkin's lymphoma survivors (HLSs) compared to controls from the general population, and to explore if CF was associated with increased mortality.
  • METHODS: HLSs (n=557) invited to participate in a survey on late effects in 1994 were divided into three groups: participants without CF (n=329), participants with CF (n=113), non-participants (n=98).
  • Mortality was increased in all groups: participants with CF: HR=4.85 (95% CI: 3.02-7.77), participants without CF: HR=4.35 (95% CI: 3.16-6.00), non-participants: HR=9.45 (95% CI: 5.44-16.41).
  • The high mortality among the non-participating HLSs indicates that serious health problems are underestimated in this group.
  • [MeSH-major] Fatigue / mortality. Hodgkin Disease / mortality. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Cause of Death. Chronic Disease. Disease-Free Survival. Female. Humans. Male. Middle Aged. Norway / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219350.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Soares A, Biasoli I, Scheliga A, Luiz RR, Costa MA, Land M, Romano S, Morais JC, Spector N: Socioeconomic inequality and short-term outcome in Hodgkin's lymphoma. Int J Cancer; 2007 Feb 15;120(4):875-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic inequality and short-term outcome in Hodgkin's lymphoma.
  • The aim of this study is to analyze the impact of the SES in Hodgkin's lymphoma (HL).
  • [MeSH-major] Health Services Accessibility / economics. Hodgkin Disease / epidemiology. Social Class. Socioeconomic Factors
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Female. Humans. Income. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131320.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Yunus SA, Usmani SZ, Ahmad S, Shahid Z: Renal involvement in non-Hodgkin's lymphoma: the Shaukat Khanum experience. Asian Pac J Cancer Prev; 2007 Apr-Jun;8(2):249-52
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal involvement in non-Hodgkin's lymphoma: the Shaukat Khanum experience.
  • BACKGROUND: Primary lymphoma of genitourinary system is rare as these organs do not contain lymphoid tissue, however secondary involvement often occurs.
  • METHODS: Medical records of 901 patients with documented NHL seen at Shaukat Khanum Memorial Cancer Hospital & Research Center during 1995-2003 were studied for the incidence, histopathological, clinical and radiological correlation of renal involvement in NHL.
  • Histology was diffuse large cell lymphoma in 12(63%) patients.
  • [MeSH-major] Kidney Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Blood Urea Nitrogen. Female. Functional Laterality. Humans. Incidence. Male. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696740.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


80. Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ: Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol; 2010 Apr;220(5):509-20
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma and is treated with chemotherapy in combination with rituximab.
  • In order to survive, lymphoma cells depend on disruption of the apoptosis pathway by mutations in apoptosis inducing genes or by continuous expression of anti-apoptotic proteins.
  • The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells without toxicity to non-malignant cells in DLBCL patients.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / antagonists & inhibitors. Lymphoma, Large B-Cell, Diffuse / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087881.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 119
  •  go-up   go-down


81. Lin SY, Hsieh MS, Chen LS, Chiu YH, Yen AM, Chen TH: Diabetes mellitus associated with the occurrence and prognosis of non-Hodgkin's lymphoma. Eur J Cancer Prev; 2007 Oct;16(5):471-8
MedlinePlus Health Information. consumer health - Diabetes Complications.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabetes mellitus associated with the occurrence and prognosis of non-Hodgkin's lymphoma.
  • The aim of this case-control study was to assess the effect of preexisting diabetes mellitus on the risk of developing non-Hodgkin's lymphoma, and also to investigate whether preexisting diabetes mellitus could further affect survival after diagnosis of non-Hodgkin's lymphoma.
  • The retrospective cohort consisted of 242 study participants with pathologically confirmed non-Hodgkin's lymphoma who were referred to the Department of Radiation Oncology in Chang-Gung Memorial Hospital between January 2000 and March 2004.
  • A logistic regression model was employed to calculate the odds ratios of the risk factors we examined and then to evaluate the association between preexisting diabetes mellitus and the occurrence of non-Hodgkin's lymphoma.
  • The results showed that preexisting diabetes mellitus was an independent risk factor for the occurrence of non-Hodgkin's lymphoma (odds ratio, 1.88; 95% confidence interval, 1.22-2.89; P=0.0045).
  • The effect of preexisting diabetes mellitus on the risk of death from non-Hodgkin's lymphoma varied with follow-up time.
  • In the current study, preexisting diabetes mellitus was an independent risk factor for the occurrence of non-Hodgkin's lymphoma, and it was also an accelerated factor for the risk of death from causes related to non-Hodgkin's lymphoma.
  • [MeSH-major] Diabetes Complications / etiology. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923820.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D'Alo' F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G: Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol; 2007 Aug;18(8):1376-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma.
  • BACKGROUND: In Hodgkin's lymphoma (HL), the production of cytokines by Reed-Sternberg cells and the surrounding tissue is thought to contribute to the biology of the disease.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496310.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


83. Ameen R, Sajnani KP, Albassami A, Refaat S: Frequencies of non-Hodgkin's lymphoma subtypes in Kuwait: comparisons between different ethnic groups. Ann Hematol; 2010 Feb;89(2):179-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequencies of non-Hodgkin's lymphoma subtypes in Kuwait: comparisons between different ethnic groups.
  • There is a wide variation in the prevalence of various subtypes of non-Hodgkin's lymphoma worldwide.
  • The aim of this study was to determine the relative frequency of different subtypes of non-Hodgkin's lymphoma in Kuwait based on the Revised European-American Lymphoma (REAL) classification.
  • From 1998 to 2006, 738 subjects were included that were registered with non-Hodgkin's lymphoma in the population-based cancer registry at the Kuwait Cancer Control Center.
  • The prevalence of different types of non-Hodgkin's lymphoma was determined based on age, sex, site of disease, and ethnicity.
  • Ethnicity groups comprised Kuwaiti Arabs, non Kuwaiti Arabs, Asians, and others.
  • The three most common subtypes in Kuwaiti Arabs were diffuse large B-cell lymphoma (46.5%), follicular lymphoma (15.5%), and mycosis fungoides (9.3%).
  • In non-Kuwaiti Arabs, the most common subtypes were diffuse large B-cell lymphoma (48%), B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia (15.8%), and follicular lymphoma (12.7%).
  • Overall, non-Kuwaiti Arabs exhibited the highest prevalence (59%), and 54% of all cases had extranodal presentation.
  • Compared to the Western world, Kuwait had a lower prevalence of follicular lymphoma, a higher prevalence of diffuse large B-cell lymphoma and extranodal presentation, and a high frequency of mycosis fungoides.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / ethnology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Kuwait / epidemiology. Male. Middle Aged. Prevalence. Sex Distribution. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711076.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Kalyan K, Basu D, Soundararaghavan J: Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification. Indian J Pathol Microbiol; 2006 Apr;49(2):203-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification.
  • The recent WHO classification of non-Hodgkin's lymphoma is based on the morphology and immunohistochemical expression of the lymphoma cells and to a lesser extent, on the molecular and cytogenetic findings.
  • Fifty-three cases of non-Hodgkin's lymphoma were included in the study.
  • The two most common types encountered were diffuse large cell lymphoma and small lymphocytic lymphoma.
  • B-cell diffuse large cell lymphoma (26%) was found to be the predominant B cell non-Hodgkin's lymphoma.
  • The commonest T-cell lymphoma was T lymphoblastic lymphoma (67%) followed by peripheral T cell angioimmunoblastic lymphoma (25%).
  • Immunohistochemistry is a useful and necessary diagnostic modality and helps subdivide prognostically different types of non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. T-Lymphocytes / immunology. T-Lymphocytes / pathology. World Health Organization

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933715.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


85. Vettori S, Staibano S, Mascolo M, Ilardi G, Valentini G: Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review. Clin Rheumatol; 2010 Jan;29(1):1-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review.
  • The occurrence of non-Hodgkin's lymphoma in systemic sclerosis is an uncommon event.
  • In our scleroderma cohort, a case of primary gastric B-cell lymphoma was diagnosed in 2007.
  • The patient was a 45-year-old woman suffering from late systemic sclerosis sine scleroderma in whom non-Hodgkin's lymphoma presented with progressive weight loss, later with gastrointestinal symptoms.
  • Subsequently, we retrospectively analyzed the charts of 251 systemic sclerosis patients consecutively admitted to our Unit from 2000 to 2008 to search for other non-Hodgkin's lymphoma cases (prevalence, 0.49%).
  • Then we performed a Pubmed search for "systemic sclerosis & non-Hodgkin's lymphoma," limited to the English language.
  • Twenty detailed cases of such an association were found, pointing out the following: non-Hodgkin's lymphoma seems to be associated to old age, female sex, diffuse cutaneous subset and early disease; B-cell lymphoma subtypes are the majority; the interval between systemic sclerosis and lymphoma onset is usually short; systemic sclerosis could present as a paraneoplastic syndrome in some cases.
  • We concluded that, although rare, the association of systemic sclerosis and non-Hodgkin's lymphoma may not be coincidental and the clinician should be aware of the risk for lymphoproliferative disorders in scleroderma patients.
  • This is the first description of non-Hodgkin's lymphoma in systemic sclerosis sine scleroderma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / complications. Scleroderma, Systemic / complications
  • [MeSH-minor] Adult. Age Factors. Aged. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Italy / epidemiology. Male. Middle Aged. Prednisone / administration & dosage. Prevalence. Retrospective Studies. Rituximab. Sex Factors. Tomography, X-Ray Computed. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1994 Mar;86(3):657-8 [8043451.001]
  • [Cites] Clin Rheumatol. 2004 Aug;23(4):348-50 [15293098.001]
  • [Cites] Chest. 1973 Sep;64(3):371-3 [4584143.001]
  • [Cites] Intern Med. 1994 Sep;33(9):557-9 [8000109.001]
  • [Cites] Acta Haematol. 2005;114(2):108-12 [16103635.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):2221-30 [19201876.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):657-66 [18311836.001]
  • [Cites] Arthritis Rheum. 1980 May;23(5):581-90 [7378088.001]
  • [Cites] Rheumatol Int. 2002 Nov;22(6):233-7 [12426661.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):85-92 [8698230.001]
  • [Cites] Dermatology. 1999;198(1):75-8 [10026408.001]
  • [Cites] J Rheumatol. 2006 Jun;33(6):1113-6 [16622904.001]
  • [Cites] South Med J. 2008 Jan;101(1):59-62 [18176294.001]
  • [Cites] J Rheumatol. 1988 Feb;15(2):202-5 [3361530.001]
  • [Cites] Arch Dermatol. 1979 Aug;115(8):950-5 [464624.001]
  • [Cites] Clin Rheumatol. 2008 Sep;27(9):1163-6 [18500435.001]
  • [Cites] Arthritis Rheum. 2000 Feb;43(2):444-51 [10693887.001]
  • [Cites] Arthritis Rheum. 1993 Apr;36(4):460-4 [8457221.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1918-27 [15188368.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):521-38 [17156403.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Eur J Haematol. 1997 Sep;59(3):194-6 [9310129.001]
  • [Cites] Ann Rheum Dis. 2003 Aug;62(8):728-31 [12860727.001]
  • [Cites] Joint Bone Spine. 2006 Jan;73(1):105-8 [15994110.001]
  • [Cites] Int J Cancer. 2008 Oct 15;123(8):1917-23 [18688859.001]
  • [Cites] Acta Derm Venereol. 1985;65(6):521-5 [2420117.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):43-8 [16501834.001]
  • [Cites] Ann Rheum Dis. 1993 Jul;52(7):531-3 [8346981.001]
  • [Cites] Clin Adv Hematol Oncol. 2004 Dec;2(12):815-9 [16166958.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Jpn J Clin Oncol. 1997 Apr;27(2):84-90 [9152796.001]
  • [Cites] Arthritis Rheum. 1985 Dec;28(12):1336-40 [4084328.001]
  • [Cites] J Dermatol. 1993 Oct;20(10):648-50 [8277043.001]
  • [Cites] Ir J Med Sci. 1982 Nov;151(11):351-2 [7152871.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1239-42 [16085569.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:152-4 [1434818.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):103-6 [14662423.001]
  • [Cites] Nephrol Dial Transplant. 1992;7(11):1166-7 [1336150.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Invest Dermatol. 2005 Oct;125(4):731-7 [16185273.001]
  • [Cites] South Med J. 1979 Nov;72(11):1463-6 [388651.001]
  • [Cites] Ann Hematol. 1996 Jul;73(1):43-5 [8695725.001]
  • [Cites] J Rheumatol. 1986 Oct;13(5):911-6 [3546686.001]
  • (PMID = 19809778.001).
  • [ISSN] 1434-9949
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 44
  •  go-up   go-down


86. Fritschi L, Benke G, Hughes AM, Kricker A, Turner J, Vajdic CM, Grulich A, Milliken S, Kaldor J, Armstrong BK: Occupational exposure to pesticides and risk of non-Hodgkin's lymphoma. Am J Epidemiol; 2005 Nov 1;162(9):849-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to pesticides and risk of non-Hodgkin's lymphoma.
  • Pesticide exposure may be a risk factor for non-Hodgkin's lymphoma, but it is not certain which types of pesticides are involved.
  • Cases with incident non-Hodgkin's lymphoma in two Australian states (n = 694) and controls (n = 694) were chosen from Australian electoral rolls.
  • Logistic regression was used to estimate the risks of non-Hodgkin's lymphoma associated with exposure to subgroups of pesticides after adjustment for age, sex, ethnic origin, and residence.
  • Substantial exposure to any pesticide was associated with a trebling of the risk of non-Hodgkin's lymphoma (odds ratio = 3.09, 95% confidence interval: 1.42, 6.70).
  • None of the exposure metrics (probability, level, frequency, duration, or years of exposure) were associated with non-Hodgkin's lymphoma.
  • Analyses of the major World Health Organization subtypes of non-Hodgkin's lymphoma suggested a stronger effect for follicular lymphoma.
  • These increases in risk of non-Hodgkin's lymphoma with substantial occupational pesticide exposure are consistent with previous work.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Occupational Diseases / epidemiology. Occupational Exposure / statistics & numerical data. Pesticides
  • [MeSH-minor] Adult. Aged. Australia / epidemiology. Case-Control Studies. Female. Humans. Hydrocarbons, Chlorinated / toxicity. Male. Middle Aged. Organophosphates / toxicity. Phenols / toxicity. Risk Assessment

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177143.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydrocarbons, Chlorinated; 0 / Organophosphates; 0 / Pesticides; 0 / Phenols
  •  go-up   go-down


87. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW: Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol; 2008 Oct;19(10):1759-64
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
  • BACKGROUND: Given the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-kappaB) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-kappaB activity, and laboratory studies suggesting synergistic antitumor effects of gemcitabine and bortezomib, we hypothesized that this combination would be efficacious in patients with relapsed or refractory HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Boronic Acids / administration & dosage. Boronic Acids / adverse effects. Bortezomib. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Proteasome Endopeptidase Complex / blood. Pyrazines / administration & dosage. Pyrazines / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 Apr;92(4):568-9 [17488673.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2482-9 [17036355.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1313-9 [17613759.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2627-8 [10561333.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Blood. 2001 May 1;97(9):2798-807 [11313274.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1145-54 [12631620.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):88-95 [12816986.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2597-8 [12826633.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] J Surg Res. 2003 Jul;113(1):88-95 [12943815.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):279-90 [15026548.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53 [15197486.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14 [15464472.001]
  • [Cites] Drugs. 1997 Sep;54(3):447-72 [9279506.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1839-42 [15878978.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1654-61 [16085692.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):533-40 [16546967.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • (PMID = 18504251.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00262860
  • [Grant] United States / NCI NIH HHS / CA / CA-102216
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC2735068
  •  go-up   go-down


88. Dreiher J, Novack V, Barachana M, Yerushalmi R, Lugassy G, Shpilberg O: Non-Hodgkin's lymphoma and residential proximity to toxic industrial waste in southern Israel. Haematologica; 2005 Dec;90(12):1709-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma and residential proximity to toxic industrial waste in southern Israel.
  • Environmental exposure has been linked to non-Hodgkin's lymphoma (NHL).
  • The risk of NHL and clinical characteristics of NHL patients were analyzed in relation to their proximity to the site.
  • [MeSH-major] Environmental Exposure. Industrial Waste. Lymphoma, Non-Hodgkin / epidemiology. Residence Characteristics. Water Pollutants, Chemical / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Geographic Information Systems. Humans. Incidence. Israel / epidemiology. Life Tables. Male. Middle Aged. Proportional Hazards Models. Risk. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Oct;93(10):e64 [18827259.001]
  • (PMID = 16330453.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Industrial Waste; 0 / Water Pollutants, Chemical
  •  go-up   go-down


89. He X, Tian C, Yang D, Xie X, Liu H: [Analysis on clinicopathologic characteristics of 216 primary extranodular non-Hodgkin's lymphoma in head and neck]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Oct;23(19):878-80
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis on clinicopathologic characteristics of 216 primary extranodular non-Hodgkin's lymphoma in head and neck].
  • OBJECTIVE: To study the clinicopathologic characteristic of the primary extranodular non Hodgkin's lymphoma in head and neck.
  • METHOD: Clinical manifestation and the characteristic of clinicopathology of 216 extranodular non-Hodgkin's lymphoma patients in head and neck were analyzed retrospectively.
  • The most common histologic subtype was NK/T cell lymphoma, which accounted for 49.5% (107 cases) of cases, secondly was diffuse large B cell lymphoma (DLBCL, 58 cases, 26.7%).
  • The most common histologic subtype in different stach groups respectively is: NK/T cell lymphoma in nasal cavity (74 cases,77.9%), DLBCL in paranasal sinus (6 cases, 50.0%), DLBCL in tonsil (27 cases, 57.4%), NK/T cell lymphoma in nasopharynx (17 cases, 44.7%), and DLBCL in lingual root (5 cases, 45.4%).
  • CONCLUSION: We conclude that primary extranodular non-Hodgkin's lymphoma is common in head and neck patients.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120872.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP Sr, Qin Q, Kilfoy B, Han J, Zheng T: Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma. Am J Epidemiol; 2007 Jun 1;165(11):1255-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma.
  • Sun exposure has been suggested to increase the risk of non-Hodgkin's lymphoma.
  • Women who reported having had a suntan experienced an increased risk of non-Hodgkin's lymphoma with increasing duration (p(trend) = 0.0062) compared with women who reported never having had a suntan.
  • An almost threefold increased risk of non-Hodgkin's lymphoma was observed among women who reported having had a suntan for less than 3 months per year and a suntan history of more than 60 years (odds ratio = 2.8, 95% confidence interval: 1.6, 4.9) compared with those who reported never having had a suntan.
  • For women who reported having spent time in strong sunlight between 9 a.m. and 3 p.m. during the summer, a 70% increased risk of non-Hodgkin's lymphoma was observed for the highest tertile of duration compared with the lowest (odds ratio = 1.7, 95% confidence interval: 1.2, 2.4).
  • The risk appears to vary by non-Hodgkin's lymphoma subtypes.
  • Further investigations of the role of ultraviolet radiation on the risk of non-Hodgkin's lymphoma are warranted.
  • [MeSH-major] Environmental Exposure / adverse effects. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Connecticut / epidemiology. Dose-Response Relationship, Radiation. Female. Humans. Logistic Models. Middle Aged. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327216.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


91. Zafar M, Mehmood A, Abassi MH, Shah SS: Primary non-Hodgkin's lymphoma of vagina associated with pregnancy. J Coll Physicians Surg Pak; 2006 Jun;16(6):424-5
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of vagina associated with pregnancy.
  • We report a case of non-Hodgkin's lymphoma (NHL) in 23 years old, 36 weeks pregnant female, who presented with a swelling in the vagina.
  • Histopathology revealed non-Hodgkin's lymphoma, diffuse large B cell type (DLBCL).
  • [MeSH-major] Hodgkin Disease / surgery. Pregnancy Complications, Neoplastic / surgery. Vaginal Neoplasms / surgery
  • [MeSH-minor] Adult. Cesarean Section. Emergencies. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787623.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


92. Rollinson S, Kesby H, Morgan GJ: Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Dec;47(12):2567-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's lymphoma.
  • Defects in members of the tri-complex are linked to increased chromosomal instability and in lymphoma predisposition.
  • Using genotyping data from six intronic or gene flanking variants in MRE11, five in NBS1 and six in RAD50 in 461 non-Hodgkin's lymphoma cases and 461 age, sex matched controls, Phase 2.1 was used to impute haplotypes for each of these genes.
  • A protective effect against follicular lymphoma was seen for the MRE11 rs601341 variant, the homozygous T allele being associated with an odds ratio (OR) of 0.50, 95% confidence interval (95% CI) 0.26 - 0.97, while a protective effect was seen for the MRE11 haplotype GCTCA (OR 0.72, 95% CI 0.53 - 0.97) for diffuse large B-cell lymphoma.
  • While reproduction of this data in other datasets is indicated, the results are indicative for a role for MRE11 in non-Hodgkin's lymphoma.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics. Haplotypes. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. DNA Repair. Female. Genotype. Humans. Linkage Disequilibrium. Male. Middle Aged. Risk

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169801.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / MRE11A protein, human; 0 / NBN protein, human; 0 / Nuclear Proteins; 0 / Rad50 protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


93. Robinson T, Lynch J, Grech E: Non-Hodgkin's lymphoma causing extrinsic pulmonary artery compression. Eur J Echocardiogr; 2008 Jul;9(4):577-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma causing extrinsic pulmonary artery compression.
  • We present the case of a patient with high grade non-Hodgkin's lymphoma who presented with progressive exertional dyspnoea.
  • [MeSH-major] Arterial Occlusive Diseases / etiology. Lymphoma, Non-Hodgkin / complications. Pulmonary Artery. Pulmonary Valve Stenosis / etiology
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18296395.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Mitarnun W, Suwiwat S, Pradutkanchana J: Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand. Asian Pac J Cancer Prev; 2006 Jan-Mar;7(1):91-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand.
  • Epstein-Barr virus (EBV) infection is highly associated with specific subtypes of malignant lymphoma.
  • In our previous report on nodal malignant lymphoma in Thailand, we found that 64% of classical Hodgkin's lymphoma (cHL), 51% of non-Hodgkin's lymphoma, T-cell (NHL-T), and 13% of non-Hodgkin's lymphoma, B-cell (NHL-B) were EBV-related.
  • In the present research, we conducted a retrospective study of primary extranodal non-Hodgkin's lymphoma of the sinonasal tract (e-NHL-ST) and primary extranodal non-Hodgkin's lymphoma of the nasopharynx (e-NHL-NP) in Southern Thailand, between 1997 and 2004.
  • EBV-encoded RNA (EBER) expression by in situ hybridization was performed in all cases and a T-cell receptor (TCR)-g gene rearrangement study was performed in NHL-T cases.
  • There were 18 cases of e-NHL-ST and 42 cases of e-NHL-NP detected by histologic and immunohistochemistry examinations.
  • The percentages of e-NHL-ST and e-NHL-NP as compared to nodal malignant lymphoma were 3.7% and 6.8%, respectively.
  • Sixteen cases (88.9%) of e-NHL-ST and 7 cases (16.7%) of e-NHL-NP were NHL-T, and the remainder were NHL-B.
  • All of the NHL-T cases in both sites were EBER-positive.
  • Two (5.4%) of the NHL-B cases in the nasopharynx showed EBER positive.
  • Monoclonal bands of the TCR-gamma gene were detected in 71.4% of the extranodal NK/T-cell lymphomas, nasal type, patients; 50.0% of peripheral T-cell lymphoma, unspecified, patients; and one case of angioimmunoblastic T-cell lymphoma.
  • This study indicates a very strong association of NHL-T in the sinonasal tract or nasopharynx with EBV infection, the link apparently being weaker in NHL-B patients.
  • The study also indicates that most cases of extranodal NK/T-cell lymphoma, nasal type, are not the germline configuration of the TCR genes.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Nasopharyngeal Neoplasms / virology. Paranasal Sinus Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. DNA, Viral / analysis. Female. Humans. In Situ Hybridization. Incidence. Lymph Nodes / pathology. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / virology. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Rate. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629523.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


95. Ara C, Coban S, Kayaalp C, Yilmaz S, Kirimlioglu V: Spontaneous intestinal perforation due to non-Hodgkin's lymphoma: evaluation of eight cases. Dig Dis Sci; 2007 Aug;52(8):1752-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous intestinal perforation due to non-Hodgkin's lymphoma: evaluation of eight cases.
  • Primary intestinal lymphoma with spontaneous perforation and after systemic chemotherapy is rare.
  • The present study summarizes retrospectively the outcome of eight free intestinal perforated patients diagnosed with intestinal non-Hodgkin's lymphoma.
  • Synchronous lymphoma was present in three patients.
  • Intestinal lymphoma might be kept in mind as a cause in free intestinal perforations.
  • Because of the high mortality rate early diagnosis and treatment are important to improve the prognosis of bowel perforation in patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Am J Surg. 1991 May;161(5):570-5 [2031540.001]
  • [Cites] Jpn J Clin Oncol. 2002 Dec;32(12):546-9 [12578905.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):252-6 [2302065.001]
  • [Cites] Am J Emerg Med. 2002 Mar;20(2):136-7 [11880888.001]
  • [Cites] Histopathology. 1988 Mar;12(3):235-52 [3366441.001]
  • [Cites] J Natl Cancer Inst. 1987 Apr;78(4):653-6 [3470541.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):259-61 [4005797.001]
  • [Cites] J Gastroenterol. 2002;37(11):939-46 [12483250.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] J Clin Gastroenterol. 2003 Oct;37(4):299-302 [14506386.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):88-90 [12729370.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Dec;21(8):707-10 [15739625.001]
  • [Cites] Surg Today. 2002;32(6):536-40 [12107782.001]
  • [Cites] JAMA. 1962 Oct 6;182:23-9 [13861046.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1999 Feb;66(1):37-40 [10097589.001]
  • [Cites] Surg Today. 2000;30(11):1030-3 [11110402.001]
  • [Cites] Ann Surg. 1980 May;191(5):593-8 [6989331.001]
  • [Cites] Med Pediatr Oncol. 1999 Apr;32(4):302-3 [10102027.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):572-3 [1728388.001]
  • [Cites] Ulus Travma Derg. 2001 Jan;7(1):74-6 [11705180.001]
  • [Cites] Indian J Gastroenterol. 2004 May-Jun;23(3):110-1 [15250572.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3175-7 [10626181.001]
  • (PMID = 17420936.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


96. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Female. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Guzicka-Kazimierczak R: [Primary gastric non-Hodgkin's lymphoma: clinical findings and prognostic factors]. Ann Acad Med Stetin; 2006;52(3):77-84; discussion 84
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric non-Hodgkin's lymphoma: clinical findings and prognostic factors].
  • PURPOSE: This work was undertaken to determine the clinical course and prognostic factors in patients with primary gastric non-Hodgkin's lymphoma (NHL).
  • The diagnosis of primary gastric NHL was made on the basis of histopathologic examination of samples collected during gastroscopy in 50 or gastrectomy in 14 patients.
  • A retrospective analysis was performed of the relationship between the outcome of treatment and age, gender, histological type of the lymphoma, clinical staging according to the original Ann Arbor classification and as modified by Stein and coworkers, functional status according to the ECOG scale, International Prognostic Index, type of lymphoma according to the classification of Kramer, and type of primary therapy.
  • The clinical picture of primary gastric non-Hodgkin's lymphoma is unrevealing.
  • 2. Age, gender, functional status, histological type of the lymphoma, and clinical stage do not correlate with treatment outcome and survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Antineoplastic Agents / therapeutic use. Female. Gastrectomy. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385352.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


98. De Roos AJ, Gold LS, Wang S, Hartge P, Cerhan JR, Cozen W, Yeager M, Chanock S, Rothman N, Severson RK: Metabolic gene variants and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev; 2006 Sep;15(9):1647-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic gene variants and risk of non-Hodgkin's lymphoma.
  • Genes involved in metabolism of environmental chemical exposures exhibit sequence variability that may mediate the risk of non-Hodgkin's lymphoma.
  • We evaluated associations between non-Hodgkin's lymphoma and 15 variants in AHR, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2E1, GSTP1, GSTM3, EPHX1, NQO1, and PON1.
  • Subjects who were heterozygous or homozygous for the cytochrome P450 gene variant CYP1B1 V432L G allele were at slightly greater risk of non-Hodgkin's lymphoma [odds ratio (OR), 1.27; 95% confidence interval (95% CI), 0.97-1.65]; these results were consistent across B-cell lymphoma subtypes and among both non-Hispanic White and Black subjects, although not statistically significant.
  • The CYP2E1 -1054T allele was associated with decreased risk of non-Hodgkin's lymphoma (CT and TT genotypes combined OR, 0.59; 95% CI, 0.37-0.93), and this pattern was observed among all histologic subtypes.
  • The numbers of cases of particular subtypes were rather small for stable estimates, but we noted that the PON1 L55M AA allele, associated with slightly increased risk of non-Hodgkin's lymphoma (variant homozygotes OR, 1.36; 95% CI, 0.96-1.95), was most strongly associated with follicular non-Hodgkin's lymphoma and T-cell lymphoma, with ORs for variant homozygotes of 2.12 and 2.93, respectively.
  • There was no overall association with non-Hodgkin's lymphoma for the other gene variants we examined.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. Aryl Hydrocarbon Hydroxylases. Aryldialkylphosphatase / genetics. Cytochrome P-450 CYP1B1. Cytochrome P-450 CYP2E1 / genetics. Cytochrome P-450 Enzyme System / genetics. Female. Genotype. Humans. Male. Middle Aged. Odds Ratio

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985026.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  •  go-up   go-down


99. Bellizzi KM, Rowland JH, Arora NK, Hamilton AS, Miller MF, Aziz NM: Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. J Clin Oncol; 2009 Feb 20;27(6):960-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma.
  • PURPOSE: To examine the prevalence and correlates of physical activity in adult survivors of aggressive non-Hodgkin's Lymphoma (NHL) and to explore the association between physical activity level and health-related quality of life (HRQOL).
  • PATIENTS AND METHODS: Physical activity and HRQOL data from 319 survivors of NHL (mean age, 59.8 years, standard deviation, +/-14.8) who were diagnosed in Los Angeles County approximately 2 to 5 years before the study was analyzed.
  • RESULTS: One quarter of survivors of NHL met public health guidelines of 150 minutes or more of moderate to vigorous exercise per week.
  • As NHL, similar to other cancers, becomes a disease that people live with as opposed to one that people die as a result of, oncologists and primary care physicians will be increasingly challenged to provide evidence-based guidance for the long-term management of the patient's health.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Sci Sports Exerc. 2000 Jan;32(1):149-56 [10647542.001]
  • [Cites] Compr Ther. 1997 Sep;23(9):605-11 [9285161.001]
  • [Cites] Psychooncology. 2000 Mar-Apr;9(2):127-36 [10767750.001]
  • [Cites] Ann Behav Med. 2001 Fall;23(4):229-46 [11761340.001]
  • [Cites] Semin Oncol Nurs. 2001 Nov;17(4):241-8 [11764707.001]
  • [Cites] Med Oncol. 2001;18(1):85-94 [11778974.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1660-8 [12721239.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3390-4 [9345021.001]
  • [Cites] Cancer Nurs. 1997 Dec;20(6):430-9 [9409065.001]
  • [Cites] Oncol Nurs Forum. 1998 Jan-Feb;25(1):107-13 [9460778.001]
  • [Cites] Semin Oncol Nurs. 1998 Nov;14(4):321-8 [9839345.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3577-87 [15908668.001]
  • [Cites] JAMA. 2005 May 25;293(20):2479-86 [15914748.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34 [15934515.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1588-95 [16030088.001]
  • [Cites] J Med Libr Assoc. 2005 Jul;93(3):353-62 [16059425.001]
  • [Cites] Psychooncology. 2005 Nov;14(11):979-91 [15744764.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8884-93 [16314649.001]
  • [Cites] CMAJ. 2006 Jul 4;175(1):34-41 [16818906.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3527-34 [16822844.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):1012-9 [16538497.001]
  • [Cites] Nurs Res. 2007 Jan-Feb;56(1):18-27 [17179870.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):225-32 [17028988.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):566-71 [17372253.001]
  • [Cites] J Aging Phys Act. 2007 Jan;15(1):103-18 [17387232.001]
  • [Cites] Acta Oncol. 2007;46(4):417-32 [17497308.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):244-50 [17493671.001]
  • [Cites] Ann Behav Med. 2007 Oct;34(2):188-99 [17927557.001]
  • [Cites] J Cancer Surviv. 2007 Mar;1(1):49-63 [18648945.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1846-52 [14600549.001]
  • [Cites] Med Sci Sports Exerc. 2004 Feb;36(2):253-60 [14767248.001]
  • [Cites] J Clin Epidemiol. 2004 Jun;57(6):571-9 [15246125.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Sep;51(3):249-61 [15331082.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] Can J Appl Sport Sci. 1985 Sep;10(3):141-6 [4053261.001]
  • [Cites] J Pers Soc Psychol. 1987 Aug;53(2):273-9 [3625467.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):979-87 [8496983.001]
  • [Cites] Med Sci Sports Exerc. 1994 Jun;26(6):649-60 [8052103.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):101-12 [7999452.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):402-7 [7823386.001]
  • [Cites] Am J Epidemiol. 1995 Jul 15;142(2):191-201 [7598119.001]
  • [Cites] Health Educ Res. 1995 Mar;10(1):51-64 [10150421.001]
  • [Cites] Br J Soc Psychol. 1995 Jun;34 ( Pt 2):199-220 [7620846.001]
  • [Cites] Health Psychol. 2000 Mar;19(2):155-64 [10762099.001]
  • (PMID = 19139438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U55/CCR921930-02; United States / NCI NIH HHS / PC / N02-PC-15105; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCI NIH HHS / CA / N01PC35139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2668638
  •  go-up   go-down


100. Li HH, Wu XX, Wang QS, Zhao Y, Bo J, Wang SH, DA WM, Yu L: [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr;14(2):298-300
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
  • The study was aimed to evaluate the effect of IEMAD (modified MIME) composed of isofosfamide, VM26 or VP16, methotrexate, cytarabine, dexamethasone or methylprednisolone, in treatment of refractory or relapsed non-Hodgkin's lymphoma.
  • Twenty-five patients with refractory or relapsed non-Hodgkin's lymphoma (11 refractory NHL patients, 14 relapsed NHL patients) were treated with IEMAD regimen.
  • It is concluded that the IEMAD (modified MIME) regimen may be a safe and effective regimen that can be used in treatment of patients with refractory or relapsed non-Hodgkin's lymphoma who did not respond to other regimens.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638201.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; OD5Q0L447W / Mitoguazone; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement